<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="v">
		<monograph id="1" status="active">
			<mono_name>valACYclovir (Rx)</mono_name>
			<info>
				<pronunciation>(val-a-sye′kloh-vir)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x210">Valtrex</tradename>
				</tradenames>
				<class type="func"> Antiviral</class>
				<class type="chem"> Synthetic purine nucleoside analog</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x31">
				<para>
					<confusion>
						<tradename id="tnidelem4x310">valACYclovir</tradename>
						<drug type="generic" refid="idelem4x310">valGANciclovir</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x38">
				<sec_title>Action:</sec_title>
				<para>Interferes with DNA synthesis by conversion to acyclovir, thereby causing decreased viral replication, time of lesional healing</para>
			</section>
			<section type="uses" id="sidelem4x43">
				<sec_title>Uses:</sec_title>
				<para>Treatment or suppression of herpes zoster (shingles), genital herpes, herpes labialis (cold sores), varicella, varicella-zoster</para>
				<section type="none" id="sidelem4x48">
					<section type="none" id="sidelem4x49">
						<sec_title>Unlabeled uses:</sec_title>
						<para> CMV with advanced HIV, posttransplant patients, Bell’s palsy, herpes simplex virus prophylaxis, acute retinal necrosis (ARN), encephalitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x54">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or acyclovir, valGANciclovir</para>
				<section type="none" id="sidelem4x59">
					<section type="none" id="sidelem4x60">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, geriatric patients, hepatic/renal disease, electrolyte imbalance, dehydration, penciclovir, famciclovir, ganciclovir, hypersensitivity, varicella</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x65">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x68">
					<section type="none" id="sidelem4x69">
						<sec_title>Herpes zoster (shingles)</sec_title>
						<section type="none" id="sidelem4x77">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x77">
									<item>
										<label>•</label>
										<para> 1 g tid × 1 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x81">
						<sec_title>Genital herpes (suppressive, initial)</sec_title>
						<section type="none" id="sidelem4x89">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x89">
									<item>
										<label>•</label>
										<para> 1 g bid × 10 days initially</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x93">
						<sec_title>Genital herpes (recurrent episodes)</sec_title>
						<section type="none" id="sidelem4x101">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x101">
									<item>
										<label>•</label>
										<para> 500 mg bid × 3 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x105">
						<sec_title>Genital herpes (suppressive therapy)</sec_title>
						<section type="none" id="sidelem4x113">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x113">
									<item>
										<label>•</label>
										<para> 1 g/day with normal immune function; 500 mg/day for those with ≤9 recurrences/yr; 500 mg bid for HIV-infected patients with CD4 count ≥100</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x117">
						<sec_title>Reduction of transmission</sec_title>
						<section type="none" id="sidelem4x125">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x125">
									<item>
										<label>•</label>
										<para> 500 mg/day for source partner</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x129">
						<sec_title>Herpes labialis</sec_title>
						<section type="none" id="sidelem4x137">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x137">
									<item>
										<label>•</label>
										<para> 2 g bid × 1 day at 1st sign of lesions</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x141">
						<sec_title>Varicella (chickenpox) in immunocompetent patients</sec_title>
						<section type="none" id="sidelem4x149">
							<label>•</label>
							<sec_title>Adolescent and child ≥2 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x149">
									<item>
										<label>•</label>
										<para> 20 mg/kg/dose tid × 5 days, max 3 g/day; start at 1st sign, preferably within 24 hr of rash</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x153">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x161">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-49 ml/min, 1 g q12hr (for regimens 1 g q8hr); 1 g q12hr × 1 day (herpes labialis); CCr 10-29 ml/min, 1 g q24hr (genital herpes/herpes zoster); 500 mg q24hr (recurrent genital herpes); CCr &lt;10 ml/min, 500 mg q24hr (genital herpes/herpes zoster), 500 mg q24hr (recurrent genital herpes)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x164">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 500 mg, 1 g</para>
					</section>
					<section type="none" id="sidelem4x169">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x173">
								<item>
									<label>•</label>
									<para>As soon as possible (herpes labialis, genital herpes); within 24 hr of rash (varicella)</para>
								</item>
								<item>
									<label>•</label>
									<para>Within 72 hr of outbreak (herpes zoster)</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Caps may be made into susp by pharmacy</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature; protect from light, moisture</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x199">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x202">
					<section type="none" id="sidelem4x203">
						<sec_title>CNS:</sec_title>
						<para> Tremors, lethargy, <emphasis style="italic">dizziness, headache,</emphasis> weakness, depression</para>
					</section>
					<section type="none" id="sidelem4x211">
						<sec_title>ENDO:</sec_title>
						<para> <emphasis style="italic">Dysmenorrhea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x218">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, diarrhea, abdominal pain, constipation, <emphasis style="italic">increased AST</emphasis></para>
					</section>
					<section type="none" id="sidelem4x228">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenic purpura, hemolytic uremic syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x235">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x242">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset unknown; terminal half-life 2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-3<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; converted to acyclovir that crosses placenta, enters breast milk; excreted in urine primarily as acyclovir; protein binding 13.5%-17.9%</para>
			</section>
			<section type="interactions" id="sidelem4x259">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> blood levels of valACYclovir—cimetidine, probenecid; only significant with renal disease</para>
				<section type="none" id="sidelem4x266">
					<section type="none" id="sidelem4x267">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x278">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x281">
					<section type="none" id="sidelem4x282">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x290">
							<label>•</label>
							<sec_title>
								<route>Infection;</route>
							</sec_title>
							<para>
								<list id="lidelem4x290">
									<item>
										<label>•</label>
										<para> characteristics of lesions; therapy should be started at 1st sign or symptom of herpes; most effective within 72 hr of outbreak</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x295">
								<item>
									<para>
										<emphasis alert="nurse">Thrombocytopenic purpura, hemolytic uremic syndrome; may be fatal</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x300">
								<item>
									<label>•</label>
									<para>C&amp;S before product therapy; product may be taken as soon as culture is taken; repeat C&amp;S after treatment; determine presence of other sexually transmitted diseases</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x305">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x310">
								<item>
									<label>•</label>
									<para>Skin eruptions: rash</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x315">
								<item>
									<label>•</label>
									<para>Allergies before treatment, reaction of each medication</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x320">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x324">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of itching, painful lesions; crusting and healed lesions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x330">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x335">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, to take as soon as remembered up to 2 hr before next dose; not to double dose, without regard to meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x340">
								<item>
									<label>•</label>
									<para>That product may be taken orally before infection occurs; that product should be taken when itching or pain occurs, usually before eruptions</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x345">
								<item>
									<label>•</label>
									<para>That partners need to be told that patient has herpes because they can become infected; that condoms must be worn to prevent reinfections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x350">
								<item>
									<label>•</label>
									<para>That product does not cure infection, just controls symptoms; that product does not prevent infection of others</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x358">
							<label>•</label>
							<sec_title>
								<route>To report CNS changes (tremors, weakness, lethargy) immediately</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>valGANciclovir (Rx)</mono_name>
			<info>
				<pronunciation>(val-gan-sy′kloh-veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x3660">Valcyte</tradename>
				</tradenames>
				<class type="func"> Antiviral</class>
				<class type="chem"> Synthetic nucleoside</class>
			</info>
			<section type="confusion" id="sidelem4x376">
				<para>
					<confusion>
						<tradename id="tnidelem4x3760">valGANciclovir</tradename>
						<drug type="generic" refid="idelem4x3760">valACYclovir</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x383">
				<sec_title>Action:</sec_title>
				<para>Metabolized to ganciclovir; inhibits replication of human cytomegalovirus in vivo and in vitro by selective inhibition of viral DNA synthesis</para>
			</section>
			<section type="uses" id="sidelem4x388">
				<sec_title>Uses:</sec_title>
				<para>Cytomegalovirus (CMV) retinitis in immunocompromised persons, including those with AIDS, after indirect ophthalmoscopy confirms diagnosis; prevention of CMV with transplantation; prevention of CMV in at-risk patient going through transplant (kidney, heart, pancreas)</para>
				<section type="none" id="sidelem4x393">
					<section type="none" id="sidelem4x394">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Colitis, Epstein-Barr virus, esophagitis, herpes simplex type 1, 2; human herpesvirus 6, 8; multicentric Castleman’s disease, varicella-zoster virus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x399">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity to ganciclovir, valACYclovir; absolute neutrophil count &lt;500/mm<emphasis style="sup">3</emphasis>; platelet count &lt;25,000/mm<emphasis style="sup">3</emphasis>; hemodialysis; liver transplantation</para>
				<section type="none" id="sidelem4x410">
					<section type="none" id="sidelem4x411">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, renal function impairment; hypersensitivity to acyclovir, penciclovir, famciclovir</para>
						<para>
							<bbw>Preexisting cytopenias, secondary malignancy, infertility, anemia, pregnancy (C)</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x426">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x429">
					<section type="none" id="sidelem4x430">
						<sec_title>Treatment of CMV</sec_title>
						<section type="none" id="sidelem4x438">
							<label>•</label>
							<sec_title>Adult and adolescent (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x438">
									<item>
										<label>•</label>
										<para> induction 900 mg bid × 21 days with food; maintenance 900 mg/day with food</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x442">
						<sec_title>Transplant (CMV prophylaxis)</sec_title>
						<section type="none" id="sidelem4x450">
							<label>•</label>
							<sec_title>Adult/adolescent &gt;16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x450">
									<item>
										<label>•</label>
										<para> 900 mg/day with food starting 10 days before transplantation until day 100 after transplantation</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x457">
							<label>•</label>
							<sec_title>Infant ≥4 mo/child/adolescent ≤16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x457">
									<item>
										<label>•</label>
										<para> give within 10 days of heart/kidney transplant; calculate dose as 7 × BSA × CCr, give as single daily dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x461">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x469">
							<label>•</label>
							<sec_title>Adult<route> PO CCr ≥60 ml/min, same as above; CCr 40-59 ml/min, 450 mg bid for 21 days, then 450 mg/day; CCr 25-39 ml/min, 450 mg/day, then 450 mg q2days; CCr 10-24 ml/min, 450 mg q2days, then 450 mg 2×/week</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x472">
						<sec_title>Available form:</sec_title>
						<para> Tabs 450 mg, powder for oral sol 50 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x477">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x480">
							<sec_title>PO tab</sec_title>
							<para>
								<list id="lidelem4x484">
									<item>
										<label>•</label>
										<para>With food for better absorption; avoid getting product on skin; do not break</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x490">
							<sec_title>Oral sol</sec_title>
							<para>
								<list id="lidelem4x494">
									<item>
										<label>•</label>
										<para>Measure 9 ml purified water in graduated cylinder, shake bottle to loosen powder, add <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> liquid, shake well, add remaining water, shake; remove child-resistant cap and push bottle adapter into neck of bottle, close with cap, give using dispenser provided</para>
									</item>
									<item>
										<label>•</label>
										<para>Store liquid in refrigerator; do not freeze; throw away any unused after 49 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x511">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x514">
					<section type="none" id="sidelem4x515">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fever,</emphasis> chills, <emphasis style="bold">coma,</emphasis><emphasis style="italic">confusion,</emphasis> abnormal thoughts, dizziness, bizarre dreams, <emphasis style="italic">headache, insomnia,</emphasis> psychosis, tremors, somnolence, <emphasis style="italic">paresthesia, weakness,</emphasis><emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x535">
						<sec_title>EENT:</sec_title>
						<para> Retinal detachment with CMV retinitis</para>
					</section>
					<section type="none" id="sidelem4x540">
						<sec_title>GI:</sec_title>
						<para> Abnormal LFTs, <emphasis style="italic">nausea, vomiting, anorexia, diarrhea, abdominal pain,</emphasis><emphasis style="bold">hemorrhage</emphasis></para>
					</section>
					<section type="none" id="sidelem4x549">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Hematuria,</emphasis> increased creatinine, BUN</para>
					</section>
					<section type="none" id="sidelem4x557">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Granulocytopenia, thrombocytopenia, irreversible neutropenia, anemia, eosinophilia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x564">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> alopecia, <emphasis style="italic">pruritus,</emphasis> urticaria, pain at site, phlebitis, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x577">
						<sec_title>MISC:</sec_title>
						<para> Local and systemic infections, <emphasis style="bold">sepsis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x584">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized to ganciclovir, which has a half-life of 3-4<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; excreted by kidneys (unchanged); crosses blood-brain barrier, CSF</para>
			</section>
			<section type="interactions" id="sidelem4x595">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: Severe granulocytopenia: immunosuppressants, zidovudine, antineoplastics, radiation; do not use together</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—dapsone, pentamidine, flucytosine, vinCRIStine, vinBLAStine, adriamycin, DOXOrubicin, amphotericin B, trimethoprim-sulfamethoxazole combinations or other nucleoside analogs, cycloSPORINE</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of both drugs—mycophenolate</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> seizures—imipenem-cilastatin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of didanosine; monitor for adverse effects, toxicity</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> renal clearance of valGANciclovir—probenecid</para>
				<section type="none" id="sidelem4x621">
					<section type="none" id="sidelem4x622">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> absorption, high-fat meal</para>
					</section>
					<section type="none" id="sidelem4x629">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> RBC/WBC, Hct/Hgb</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x640">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x643">
					<section type="none" id="sidelem4x644">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x652">
							<para>
								<list id="lidelem4x652">
									<item>
										<label>•</label>
										<para>CMV retinitis by ophthalmoscopy before beginning treatment, q2wk; culture for CMV retinitis
<bbw>Leukopenia/neutropenia/thrombocytopenia: WBCs, platelets q2days during 2×/day dosing, then q1wk; leukopenia with daily WBC count in patients with prior leukopenia with other nucleoside analogs or for whom leukopenia counts are &lt;1000 cells/mm3 at start of treatment</bbw>

<bbw>
												<emphasis alert="lifethreat">Malignancy:</emphasis> monitor for malignancy, avoid accidental exposure of broken, crushed tabs, powder, if these were in contact with skin, wash well with soap and water</bbw>

<bbw>Pregnancy: considered potentially teratogenic; adequate contraception should be used</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x686">
								<item>
									<label>•</label>
									<para>Serum creatinine or CCr ≥q2wk</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x691">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x695">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of CMV</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x701">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x706">
								<item>
									<label>•</label>
									<para>That product does not cure condition; that regular ophthalmologic and blood tests necessary</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x711">
								<item>
									<label>•</label>
									<para>That major toxicities may necessitate discontinuing product
<bbw>To use contraception during treatment; that infertility may occur; that men should use barrier contraception for 90 days after treatment</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x725">
								<item>
									<label>•</label>
									<para>To take with food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x731">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias: bruising, bleeding, petechiae; seizures, dizziness; to avoid hazardous activities</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x736">
								<item>
									<label>•</label>
									<para>To use sunscreen to prevent burns</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>valproate (Rx)</mono_name>
			<info>
				<pronunciation>(val′proh-ate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x7460">Depacon</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="4" status="active">
			<mono_name>valproic acid (Rx)</mono_name>
			<info>
				<pronunciation>(val′proh-ik)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x7531">Depakene</tradename>
					<tradename id="tnidelem4x7530">Stavzor</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="5" status="active">
			<mono_name>divalproex sodium (Rx)</mono_name>
			<info>
				<pronunciation>(dye-val′proh-ex)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x7602">Depakote</tradename>
					<tradename id="tnidelem4x7601">Depakote ER</tradename>
					<tradename id="tnidelem4x7600">
						<country code="CAN">Epival </country>
					</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant, vascular headache suppressant</class>
				<class type="chem"> Carboxylic acid derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x772">
				<sec_title>Action:</sec_title>
				<para>Increases levels of γ-aminobutyric acid (GABA) in the brain, which decreases seizure activity</para>
			</section>
			<section type="uses" id="sidelem4x777">
				<sec_title>Uses:</sec_title>
				<para>Simple (petit mal), complex (petit mal), absence, mixed, seizures; manic episodes associated with bipolar disorder, prophylaxis of migraine, adjunct for schizophrenia, tardive dyskinesia, aggression in children with ADHD, organic brain syndrome, mania, migraines; tonic-clonic (grand mal), myoclonic seizures</para>
				<section type="none" id="sidelem4x782">
					<section type="none" id="sidelem4x783">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Rectal for seizures (valproic acid)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x788">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, urea cycle disorders</para>
				<para>
					<bbw>Pregnancy (D), hepatic disease, pancreatitis</bbw>
				</para>
				<section type="none" id="sidelem4x803">
					<section type="none" id="sidelem4x804">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, geriatric patients</para>
						<para>
							<bbw>Children &lt;2 yr</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x819">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x822">
					<section type="none" id="sidelem4x823">
						<sec_title>Epilepsy</sec_title>
						<section type="none" id="sidelem4x831">
							<label>•</label>
							<sec_title>Adult and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x831">
									<item>
										<label>•</label>
										<para> 10-15 mg/kg/day in 2-3 divided doses, may increase by 5-10 mg/kg/day weekly, max 60 mg/kg/day in 2-3 divided doses;  ≤20 mg/min over 1 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x838">
						<sec_title>Status epilepticus refractory to diazepam IV (unlabeled)</sec_title>
						<section type="none" id="sidelem4x846">
							<label>•</label>
							<sec_title>Adult<route> RECT</route></sec_title>
							<para>
								<list id="lidelem4x846">
									<item>
										<label>•</label>
										<para> 400-600 mg PR as enema or wax-based suppository (not commercially available)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x853">
							<label>•</label>
							<sec_title>Child<route> RECT</route></sec_title>
							<para>
								<list id="lidelem4x853">
									<item>
										<label>•</label>
										<para> 20 mg/kg/dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x857">
						<sec_title>Mania (divalproex sodium)</sec_title>
						<section type="none" id="sidelem4x865">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x865">
									<item>
										<label>•</label>
										<para> 750 mg/day in divided doses, max 60 mg/kg/day or 3000 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x869">
						<sec_title>Mania (valproic acid: Stavzor)</sec_title>
						<section type="none" id="sidelem4x877">
							<label>•</label>
							<sec_title>Adult<route> DEL REL CAP</route></sec_title>
							<para>
								<list id="lidelem4x877">
									<item>
										<label>•</label>
										<para> 750 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x881">
						<sec_title>Migraine (divalproex sodium)</sec_title>
						<section type="none" id="sidelem4x889">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x889">
									<item>
										<label>•</label>
										<para> 250 mg bid, may increase to 1000 mg/day if needed or 500 mg (Depakote ER) daily × 7 days, then 1000 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x893">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="italic">Valproate:</emphasis> inj 100 mg/ml; <emphasis style="italic">valproic acid:</emphasis> caps 250 mg; oral solution 250 mg/5 ml; del rel cap (Stavzor) 125, 250, 500 mg; <emphasis style="italic">divalproex:</emphasis> gastro-resistant tabs 125, 250, 500 mg; ext rel tabs 250, 500 mg cap gastro-resistant; sprinkle cap 125 mg</para>
					</section>
					<section type="none" id="sidelem4x907">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x910">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x914">
									<item>
										<label>•</label>
										<para>Swallow tabs or caps whole; do not break, crush, or chew ext rel tabs</para>
									</item>
									<item>
										<label>•</label>
										<para>Sprinkle cap contents on food</para>
									</item>
									<item>
										<label>•</label>
										<para>Oral solution alone; do not dilute with carbonated beverage; do not give oral solution to patients with sodium restrictions</para>
									</item>
									<item>
										<label>•</label>
										<para>Give with food or milk to decrease GI symptoms</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x935">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x939">
									<item>
										<label>•</label>
										<para>Dilute dose with ≥50 ml D<emphasis style="inf">5</emphasis>W, NS, LR</para>
									</item>
									<item>
										<label>•</label>
										<para>Run over 60 min (20 mg/min)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x953">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x956">
					<section type="none" id="sidelem4x957">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Sedation, drowsiness,</emphasis> dizziness, headache, incoordination, depression, hallucinations, behavioral changes, tremors, aggression, weakness, <emphasis style="bold">coma, suicidal ideation, hypothermia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x967">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension, chest pain, palpitations, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x972">
						<sec_title>EENT:</sec_title>
						<para> Visual disturbances, taste perversion</para>
					</section>
					<section type="none" id="sidelem4x977">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, constipation, diarrhea, dyspepsia,</emphasis> anorexia, cramps, <emphasis style="bold">hepatic failure, pancreatitis, toxic hepatitis,</emphasis> stomatitis, weight gain, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x988">
						<sec_title>GU:</sec_title>
						<para> Enuresis, irregular menses</para>
					</section>
					<section type="none" id="sidelem4x993">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, lymphocytosis,</emphasis> increased PT, bruising, epistaxis, <emphasis style="bold">pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1003">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> alopecia, photosensitivity, dry skin</para>
					</section>
					<section type="none" id="sidelem4x1011">
						<sec_title>META:</sec_title>
						<para> Hyperammonemia, SIADH</para>
					</section>
					<section type="none" id="sidelem4x1016">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1021">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver; excreted by kidneys, in breast milk; crosses placenta; half-life 6-16 hr; 90% protein binding</para>
				<section type="none" id="sidelem4x1026">
					<section type="none" id="sidelem4x1027">
						<sec_title>PO:</sec_title>
						<para> Peak 4 hr (regular rel); 4-17 hr (ext rel)</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1032">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> valproic acid toxicity level—erythromycin, felbamate, salicylates, NSAIDs, rifampin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, opioids, barbiturates, antihistamines, MAOIs, sedative/hypnotics, tricyclics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of, possible toxicity phenytoin, carBAMazepine, ethosuximide, barbiturates, zidovudine, LORazepam, rufinamide, lamoTRIgine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> seizure threshold—tricyclics</para>
				<section type="none" id="sidelem4x1055">
					<section type="none" id="sidelem4x1056">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False positive:</emphasis> ketones, urine</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> thyroid function tests</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, bleeding time, ammonia</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> sodium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1075">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1078">
					<section type="none" id="sidelem4x1079">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1087">
							<label>•</label>
							<sec_title>Seizure disorder</sec_title>
							<para>
								<list id="lidelem4x1087">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Seizure disorder:</emphasis> location, aura, activity, duration; seizure precautions should be in place</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1092">
								<item>
									<para>
										<emphasis alert="nurse">Mental status: bipolar disorder: mood, activity, sleeping/eating, behavior; suicidal thoughts/behaviors</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1100">
							<label>•</label>
							<sec_title>Migraines</sec_title>
							<para>
								<list id="lidelem4x1100">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Migraines:</emphasis> frequency, intensity, alleviating factors</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1104">
								<item>
									<label>•</label>
									<para>Blood studies: Hct, Hgb, RBC, serum folate, PT/PTT, serum ammonia, platelets, vit D if patient receiving long-term therapy
<bbw>Hepatic studies: AST, ALT, bilirubin; hepatic failure has occurred; monitor for fever, anorexia, vomiting, lethargy, jaundice of skin, eyes that may occur during treatment, those with organic brain disorders, mental retardation, child &lt;2 yr are at greater risk</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1121">
							<label>•</label>
							<sec_title>Hyperammonemic encephalopathy<route> can be fatal in those with urea cycle disorders (UCD); lethargy, confusion, coma, CV, respiratory changes; discontinue</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1127">
							<para>
								<list id="lidelem4x1127">
									<item>
										<label>•</label>
										<para>Blood levels: therapeutic level 50-125 mcg/ml, during seizures
<bbw>
												<emphasis alert="lifethreat">Pancreatitis;</emphasis> may be fatal; report immediately nausea, vomiting, anorexia, abdominal pain; may occur anytime during treatment or for several months/years after discontinuing treatment</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1140">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1144">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased seizures</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1150">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1155">
								<item>
									<label>•</label>
									<para>That physical dependency may result from extended use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1160">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities that require alertness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1165">
								<item>
									<label>•</label>
									<para>To drink plenty of fluids</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1173">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue medication quickly after long-term use because seizures may result</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x1188">
							<label>•</label>
							<sec_title>
								<route>To use contraception while taking this product; pregnancy (D)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x1194">
							<label>•</label>
							<sec_title>Overdose symptoms<route> heart block, coma</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1200">
							<label>•</label>
							<sec_title>
								<route>To report immediately suicidal thoughts/behaviors</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>valsartan (Rx)</mono_name>
			<info>
				<pronunciation>(val′sahr-tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x12080">Diovan</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin II receptor antagonist (Type AT)</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1221">
				<para>
					<confusion>
						<tradename id="tnidelem4x12210">Diovan</tradename>
						<drug type="generic" refid="idelem4x12210">Dioval</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1225">
				<sec_title>Action:</sec_title>
				<para>Blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II; selectively blocks the binding of angiotensin II to the AT<emphasis style="inf">1</emphasis> receptor found in tissues</para>
			</section>
			<section type="uses" id="sidelem4x1233">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination in patients &gt;6 yr, CHF, post MI with left ventricular dysfunction/failure in stable patients</para>
			</section>
			<section type="contra" id="sidelem4x1238">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, severe hepatic disease, bilateral renal artery stenosis</para>
				<para>
					<bbw>Pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x1254">
					<section type="none" id="sidelem4x1255">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, hypersensitivity to ACE inhibitors; CHF, hypertrophic cardiomyopathy aortic/mitral valve stenosis, CAD, angioedema, renal/hepatic disease, hyperkalemia, hypovolemia, African descent</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1260">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1263">
					<section type="none" id="sidelem4x1264">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x1272">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1272">
									<item>
										<label>•</label>
										<para> 80 or 160 mg/day alone or in combination with other antihypertensives, may increase to 320 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1279">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1279">
									<item>
										<label>•</label>
										<para> adjust on clinical response; may start with lower dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1286">
							<label>•</label>
							<sec_title>Child and adolescent 6-16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1286">
									<item>
										<label>•</label>
										<para> 1.3 mg/kg/day, max 40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1290">
						<sec_title>CHF</sec_title>
						<section type="none" id="sidelem4x1298">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1298">
									<item>
										<label>•</label>
										<para> 40 mg bid, up to 160 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1302">
						<sec_title>Post MI</sec_title>
						<section type="none" id="sidelem4x1310">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1310">
									<item>
										<label>•</label>
										<para> 20 mg bid as early as 12 hr post MI, may be titrated within 7 days to 40 mg bid, then titrate to maintenance of 160 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1314">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 40, 80, 160, 320 mg</para>
					</section>
					<section type="none" id="sidelem4x1319">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1323">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1329">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1332">
					<section type="none" id="sidelem4x1333">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, insomnia,</emphasis> drowsiness, vertigo, headache, fatigue</para>
					</section>
					<section type="none" id="sidelem4x1341">
						<sec_title>CV:</sec_title>
						<para> Angina pectoris, 2nd-degree AV block, <emphasis style="bold">cerebrovascular accident,</emphasis> hypotension, <emphasis style="bold">MI, <emphasis style="italic">dysrhythmias</emphasis></emphasis></para>
					</section>
					<section type="none" id="sidelem4x1353">
						<sec_title>EENT:</sec_title>
						<para> Conjunctivitis</para>
					</section>
					<section type="none" id="sidelem4x1358">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> abdominal pain, nausea, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1368">
						<sec_title>GU:</sec_title>
						<para> Impotence, <emphasis style="bold">nephrotoxicity, renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1375">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="italic">Anemia,</emphasis> neutropenia</para>
					</section>
					<section type="none" id="sidelem4x1383">
						<sec_title>META:</sec_title>
						<para> Hyperkalemia</para>
					</section>
					<section type="none" id="sidelem4x1388">
						<sec_title>MISC:</sec_title>
						<para> Vasculitis, <emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1395">
						<sec_title>MS:</sec_title>
						<para> Cramps, myalgia, pain, stiffness</para>
					</section>
					<section type="none" id="sidelem4x1400">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1407">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset up to 2 hr; peak 2-4 hr; duration 24 hr; extensively metabolized; protein binding 95%; half-life 6 hr; excreted in feces, urine, breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x1412">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x1420">
					<label>•</label>
					<sec_title>
						<route>Do not use with aliskiren</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of lithium, antidiabetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium-sparing diuretics, potassium supplements, ACE inhibitors, cycloSPORINE</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> Valsartan level—rifampin, ritonavir, gemfibrozil, telithromycin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effects—NSAIDs, salicylates</para>
				<section type="none" id="sidelem4x1439">
					<section type="none" id="sidelem4x1440">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra, ma huang</para>
					</section>
					<section type="none" id="sidelem4x1451">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> hyperkalemia—salt substitutes with potasssium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1458">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1461">
					<section type="none" id="sidelem4x1462">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x1467">
								<item>
									<label>•</label>
									<para>B/P, pulse q4hr lying, sitting, standing; note rate, rhythm, quality periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1472">
								<item>
									<label>•</label>
									<para>Blood studies; BUN, creatinine, LFTs, potassium total/direct bilirubin before treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1480">
							<label>•</label>
							<sec_title>Angioedema<route> facial swelling; SOB; edema in feet, legs daily</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1483">
								<item>
									<label>•</label>
									<para>Skin turgor, dryness of mucous membranes for hydration status; correct volume depletion before initiating therapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1488">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1492">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1498">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1503">
								<item>
									<label>•</label>
									<para>To comply with dosage schedule, even if feeling better; that, if dose is missed, to take it as soon as possible unless it is within 1 hr of next dose</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1511">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of fever, swelling of hands or feet, irregular heartbeat, chest pain, dizziness, persistent cough</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1514">
								<item>
									<label>•</label>
									<para>That excessive perspiration, dehydration, diarrhea may lead to fall in blood pressure; to consult prescriber if these occur; to maintain hydration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1519">
								<item>
									<label>•</label>
									<para>That product may cause dizziness, fainting, lightheadedness; to rise slowly to sitting or standing position to minimize orthostatic hypotension; to take B/P readings</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1524">
								<item>
									<label>•</label>
									<para>To avoid potassium supplements and foods, salt substitutes
<bbw>Not to take product if pregnant (D) or breastfeeding</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1541">
							<label>•</label>
							<sec_title>Overdose symptoms<route> bradycardia or tachycardia, circulatory collapse</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>vancomycin (Rx)</mono_name>
			<info>
				<pronunciation>(van-koe-mye′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x15490">Vancocin</tradename>
				</tradenames>
				<class type="func"> Antiinfective—miscellaneous</class>
				<class type="chem"> Tricyclic glycopeptide</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x1559">
				<sec_title>Action:</sec_title>
				<para>Inhibits bacterial cell-wall synthesis, blocks glycopeptides</para>
			</section>
			<section type="uses" id="sidelem4x1564">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="italic">Actinomyces</emphasis> sp., <emphasis style="italic">Bacillus</emphasis> sp., <emphasis style="italic">Clostridium difficile, Clostridium</emphasis> sp., <emphasis style="italic">enterococcus faecalis, Enterococcus faecium, Enterococcus</emphasis> sp., <emphasis style="italic">Lactobacillus</emphasis> sp., <emphasis style="italic">Listeria monocytogenes, Staphylococcus aureus (MRSA), Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Staphylococcus</emphasis> sp., <emphasis style="italic">Streptococcus agalactiae (group B streptococci), Streptococcus bovis, Streptococcus pneumoniae, Streptococcus pyogenes (group A beta-hemolytic streptococci), Viridans streptococci;</emphasis> may be effective against <emphasis style="italic">Corynebacterium jeikeium, Corynebacterium</emphasis> sp., pseudomembranous colitis, staphylococcal enterocolitis, endocarditis prophylaxis for dental procedures, bacteremia, joint/bone infections, osteomyelitis, pneumonia, septicemia</para>
				<section type="none" id="sidelem4x1592">
					<section type="none" id="sidelem4x1593">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Bacterial infection prophylaxis, brain abscess, endocarditis prophylaxis, meningitis, orthopedic device related infection, peritonitis, surgical infection prophylaxis, vancomycin desensitization, ventriculitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1598">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or corn</para>
				<section type="none" id="sidelem4x1603">
					<section type="none" id="sidelem4x1604">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>) PO, (C) IV; breastfeeding, neonates, geriatric patients, renal disease, hearing loss</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1609">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1612">
					<section type="none" id="sidelem4x1613">
						<sec_title>Serious staphylococcal infections</sec_title>
						<section type="none" id="sidelem4x1621">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1621">
									<item>
										<label>•</label>
										<para> 500 mg q6-8hr or 1 g q12hr or 15-20 mg/kg q12hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1628">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1628">
									<item>
										<label>•</label>
										<para> 40-60 mg/kg/day divided q6-8hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1635">
							<label>•</label>
							<sec_title>Neonate<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1635">
									<item>
										<label>•</label>
										<para> 15 mg/kg initially, then 10 mg/kg q8-24hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1639">
						<sec_title>Pseudomembranous/staphylococcal enterocolitis</sec_title>
						<section type="none" id="sidelem4x1647">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1647">
									<item>
										<label>•</label>
										<para> 125 mg qid × 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1654">
							<label>•</label>
							<sec_title>Child<route> PO (unlabeled)</route></sec_title>
							<para>
								<list id="lidelem4x1654">
									<item>
										<label>•</label>
										<para> 40 mg/kg/day divided q6hr × 7-10 days, max 2 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1658">
						<sec_title>Endocarditis prophylaxis</sec_title>
						<section type="none" id="sidelem4x1666">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1666">
									<item>
										<label>•</label>
										<para> 2 g divided</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1673">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1673">
									<item>
										<label>•</label>
										<para> 20 mg/kg over 1 hr given 1 hr before procedure</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1677">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x1685">
							<label>•</label>
							<sec_title>Adult<route> IV 15-20 mg/kg loading dose in seriously ill; individualize all other doses</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1688">
						<sec_title>Available forms:</sec_title>
						<para> Cap 125, 250 mg; powder for inj 500 mg, 1, 5, 10 g; Dextrose sol for inj 500 mg/100 ml, 750 mg/150 ml, 1 g/200 ml</para>
					</section>
					<section type="none" id="sidelem4x1693">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1698">
								<item>
									<label>•</label>
									<para>Use only for susceptible organisms to prevent product-resistant bacteria</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1703">
								<item>
									<label>•</label>
									<para>Antihistamine if red-man syndrome occurs: decreased B/P, flushing of neck, face; stop or slow infusion</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1708">
								<item>
									<label>•</label>
									<para>Dose based on serum concentration</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1716">
							<label>•</label>
							<sec_title>PO</sec_title>
							<para>
								<list id="lidelem4x1716">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">PO:</emphasis> without regard to food, swallow whole</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1720">
								<item>
									<label>•</label>
									<para>Store at room temperature for ≤2 wk after reconstitution</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1725">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x1729">
									<item>
										<label>•</label>
										<para>After reconstitution with 10 ml sterile water for inj (500 mg/10 ml); further dilution is needed for IV, 500 mg/100 ml 0.9% NaCl, D<emphasis style="inf">5</emphasis>W given as intermittent infusion over 1 hr; decrease rate of infusion if red-man syndrome occurs</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1738">
							<sec_title>Continuous IV INFUSION route (unlabeled)</sec_title>
							<para>
								<list id="lidelem4x1742">
									<item>
										<label>•</label>
										<para>May infuse 1-2 g in volume to give over 24 hr if intermittent IV route cannot be used</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acetylcysteine, acyclovir, alatrofloxacin, aldesleukin, alemtuzumab, alfentanil, allopurinol, alprostadil, amifostine, amikacin, amino acids injection, aminocaproic acid, amiodarone, amoxicillin-clavulanate, amsacrine, anidulafungin, argatroban, ascorbic acid injection, atenolol, atracurium, atropine, azithromycin, benztropine, bleomycin, bretylium, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, caspofungin, cefpirome, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clarithromycin, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAUNOrubicin liposome, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doripenem, doxacurium, doxapram, DOXOrubicin, DOXOrubicin liposomal, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, folic acid (as sodium salt), gallium, gemcitabine, gentamicin, glycopyrrolate, granisetron, HYDROmorphone, hydrOXYzine, ifosfamide, insulin, regular, irinotecan, isoproterenol, isosorbide, ketamine, labetalol, lactated Ringer’s injection, lepirudin, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, metaraminol, methyldopate, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoXANtrone, morphine, morphine, multiple vitamins injection, mycophenolate, nalbuphine, naloxone, nesiritide, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ofloxacin, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel (solvent/surfactant), palonosetron, pamidronate, pancuronium, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentamidine, pentazocine, PENTobarbital, perphenazine, PHENobarbital, phentolamine, phenylephrine, phytonadione, piritramide, polymyxin B, potassium acetate/chloride, procainamide, prochlorperazine, promethazine, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, remifentanil, rifampin, Ringer’s injection, riTUXimab, sodium acetate/bicarbonate/citrate, succinylcholine, SUFentanil, tacrolimus, teniposide, thiamine, thiotepa, tigecycline, tirofiban, TNA (3-in-1), tobramycin, tolazoline, TPN (2-in-1), trastuzumab, urapidil, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1752">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1755">
					<section type="none" id="sidelem4x1756">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x1761">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Cardiac arrest, vascular collapse (rare),</emphasis> hypotension, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x1769">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Ototoxicity, permanent deafness,</emphasis> tinnitus, nystagmus</para>
					</section>
					<section type="none" id="sidelem4x1777">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Nausea, pseudomembranous colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1784">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotoxicity,</emphasis><emphasis style="italic">increased BUN, creatinine, albumin,</emphasis><emphasis style="bold">fatal uremia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1795">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, eosinophilia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1802">
						<sec_title>INTEG:</sec_title>
						<para> Chills, fever, rash, thrombophlebitis at inj site, urticaria, pruritus, <emphasis style="bold">necrosis (red-man syndrome),</emphasis> skin/subcutaneous tissue disorders</para>
					</section>
					<section type="none" id="sidelem4x1810">
						<sec_title>MS:</sec_title>
						<para> Back pain</para>
					</section>
					<section type="none" id="sidelem4x1815">
						<sec_title>RESP:</sec_title>
						<para> Wheezing, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x1820">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, superinfection</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1827">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x1830">
					<section type="none" id="sidelem4x1831">
						<sec_title>PO:</sec_title>
						<para> Absorption poor</para>
					</section>
					<section type="none" id="sidelem4x1836">
						<sec_title>IV:</sec_title>
						<para> Onset rapid, peak 1 hr, half-life 4-8 hr, excreted in urine (active form)</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1841">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x1851">
					<label>•</label>
					<sec_title>
						<route>Do not use with cholestyramine, colestipol, cidofovir</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> lactic acidosis—metFORMIN</para>
				<section type="none" id="sidelem4x1858">
					<section type="none" id="sidelem4x1859">
						<sec_title>Increase:</sec_title>
						<para> neuromuscular effects—nondepolarizing muscle relaxants</para>
					</section>
					<section type="none" id="sidelem4x1864">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN/creatinine, eosinophils</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1875">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1878">
					<section type="none" id="sidelem4x1879">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1887">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x1887">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> WBC, urine, stools, sputum, characteristics of wound throughout treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1891">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report hematuria, oliguria; nephrotoxicity may occur, BUN, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1896">
								<item>
									<label>•</label>
									<para>Serum levels: peak 1 hr after 1-hr infusion 25-40 mg/L, trough before next dose 5-10 mg/L, especially in renal disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1901">
								<item>
									<label>•</label>
									<para>C&amp;S</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1906">
								<item>
									<label>•</label>
									<para>Auditory function during, after treatment; hearing loss, ringing, roaring in ears; product should be discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1911">
								<item>
									<label>•</label>
									<para>B/P during administration; sudden drop may indicate red-man syndrome</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1916">
								<item>
									<label>•</label>
									<para>Skin eruptions</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1924">
							<label>•</label>
							<sec_title>Red-man syndrome<route> flushing of neck, face, upper body, arms, back, may lead to anaphylaxis; slow IV infusion to &gt;1 hr</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1927">
								<item>
									<label>•</label>
									<para>EPINEPHrine, suction, tracheostomy set, endotracheal intubation equipment on unit; anaphylaxis may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1932">
								<item>
									<label>•</label>
									<para>Adequate intake of fluids (2 L/day) to prevent nephrotoxicity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1937">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1941">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, sore throat; negative culture</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1947">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1951">
								<item>
									<label>•</label>
									<para>About all aspects of product therapy; about the need to complete entire course of medication to ensure organism death (7-10 days); that culture may be taken after completed course of medication</para>
								</item>
								<item>
									<label>•</label>
									<para>To report sore throat, fever, fatigue; could indicate superinfection</para>
								</item>
								<item>
									<label>•</label>
									<para>That product must be taken in equal intervals around the clock to maintain blood levels</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>vardenafil (Rx)</mono_name>
			<info>
				<pronunciation>(var-den′a-fil)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x19721">Levitra</tradename>
					<tradename id="tnidelem4x19720">Staxyn</tradename>
				</tradenames>
				<class type="func"> Erectile dysfunction agent</class>
				<class type="chem"> Phosphodiesterase type 5 inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x1982">
				<sec_title>Action:</sec_title>
				<para>Inhibits phosphodiesterase type 5 (PDE5), enhances erectile function by increasing the amount of cGMP, which in turn causes smooth muscle relaxation and increased blood flow into the corpus cavernosum</para>
			</section>
			<section type="uses" id="sidelem4x1987">
				<sec_title>Uses:</sec_title>
				<para>Treatment of erectile dysfunction</para>
			</section>
			<section type="contra" id="sidelem4x1992">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, coadministration of α-blockers or nitrates, renal failure, congenital or acquired QT prolongation</para>
				<section type="none" id="sidelem4x1997">
					<section type="none" id="sidelem4x1998">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>); not indicated for women, children, or newborns; hepatic impairment, retinitis pigmentosa, anatomical penile deformities, sickle cell anemia, leukemia, multiple myeloma, bleeding disorders, active peptic ulceration, CV/renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2003">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2011">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2011">
							<item>
								<label>•</label>
								<para> 10 mg taken 1 hr before sexual activity; dose may be reduced to 5 mg or increased to max 20 mg; max dosing frequency once daily; orally disintegrating tab 10 mg 60 min before sexual activity; do not use with potent CYP3A4 inhibitors</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2018">
					<label>•</label>
					<sec_title>Geriatric &gt;65 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2018">
							<item>
								<label>•</label>
								<para> 5 mg initially, titrated as needed/tolerated</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2022">
					<section type="none" id="sidelem4x2023">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x2031">
							<label>•</label>
							<sec_title>Adult<route> PO (Child-Pugh B) 5 mg, max 10 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2034">
						<sec_title>Concomitant medications</sec_title>
						<para>
							<list id="lidelem4x2038">
								<item>
									<label>•</label>
									<para>Ritonavir, max 2.5 mg q72hr; for indinavir, ketoconazole 400 mg/day and itraconazole 400 mg/day, max 2.5 mg/day; for ketoconazole 200 mg/day, itraconazole 200 mg/day and erythromycin max 5 mg/day</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2044">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5, 5, 10, 20 mg; orally disintegrating tab 10 mg</para>
					</section>
					<section type="none" id="sidelem4x2049">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2054">
								<item>
									<label>•</label>
									<para>Approximately 1 hr before sexual activity; do not use more than once daily; orally disintegrating tabs are not interchangeable with film-coated tabs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2059">
								<item>
									<label>•</label>
									<para>Without regard to food; avoid taking with high-fat meal</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2067">
							<label>•</label>
							<sec_title>Oral disintegrating tab</sec_title>
							<para>
								<list id="lidelem4x2067">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral disintegrating tab:</emphasis> place on tongue, allow to dissolve, do not use water</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2071">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2074">
					<section type="none" id="sidelem4x2075">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, flushing, dizziness, insomnia,</emphasis><emphasis style="bold">seizures,</emphasis> transient global amnesia</para>
					</section>
					<section type="none" id="sidelem4x2085">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="bold">MI, CV collapse,</emphasis> chest pain</para>
					</section>
					<section type="none" id="sidelem4x2093">
						<sec_title>EENT:</sec_title>
						<para> Conjunctivitis, tinnitus, photophobia, diminished vision, glaucoma, hearing loss</para>
					</section>
					<section type="none" id="sidelem4x2098">
						<sec_title>GU:</sec_title>
						<para> Abnormal ejaculation, priapism</para>
					</section>
					<section type="none" id="sidelem4x2103">
						<sec_title>MISC:</sec_title>
						<para> Rash, GERD, GGTP increased, <emphasis style="bold">NAION (nonarteritic ischemic optic neuropathy),</emphasis> dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x2111">
						<sec_title>MS:</sec_title>
						<para> Myalgia, arthralgia, neck pain</para>
					</section>
					<section type="none" id="sidelem4x2116">
						<sec_title>RESP:</sec_title>
						<para> Rhinitis, sinusitis, dyspnea, pharyngitis, epistaxis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2121">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed, bioavailability 15%, protein binding 95%, metabolized by liver, terminal half-life 4-5 hr, onset 20 min, peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, duration &lt;5 hr, reduced absorption with high-fat meal, primarily excreted in feces (91%-95%)</para>
			</section>
			<section type="interactions" id="sidelem4x2138">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Do not use with nitrates because of unsafe decrease in B/P, which could result in MI or stroke</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Serious dysrhythmias: class IA/III antiarrhythmics, clarithromycin, droperidol, procainamide, quiNIDine, quinolones; do not use concurrently</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—α-blockers, protease inhibitors, metoprolol, NIFEdipine, alcohol, amLODIPine, angiotensin II receptor blockers; do not use concurrently</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> vardenafil levels—erythromycin, azole antifungals (ketoconazole, itraconazole), cimetidine, antiretroviral protease inhibitors</para>
				<section type="none" id="sidelem4x2159">
					<section type="none" id="sidelem4x2160">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption—high-fat meal</para>
					</section>
					<section type="none" id="sidelem4x2167">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CK</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2174">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2177">
					<section type="none" id="sidelem4x2178">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2183">
								<item>
									<label>•</label>
									<para>Erectile dysfunction and cause before treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2189">
								<item>
									<para>
										<emphasis alert="nurse">Any severe loss of vision while taking this or similar products; products should not be used</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2195">
								<item>
									<para>
										<emphasis alert="nurse">Use of organic nitrates that should not be used with this product</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2200">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2205">
								<item>
									<label>•</label>
									<para>That product does not protect against STDs, including HIV</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2210">
								<item>
									<label>•</label>
									<para>That product absorption is reduced with high-fat meal</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2218">
							<label>•</label>
							<sec_title>
								<route>That product should not be used with nitrates in any form; to inform physician of all medications being taken</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2221">
								<item>
									<label>•</label>
									<para>That product has no effect in the absence of sexual stimulation; that patient should seek immediate medical attention if erections last &gt;4 hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2227">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber immediately and stop taking product if vision loss occurs</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>varenicline (Rx)</mono_name>
			<info>
				<pronunciation>(var-e-ni′kleen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x22371">
						<country code="CAN">Champix </country>
					</tradename>
					<tradename id="tnidelem4x22370">Chantix</tradename>
				</tradenames>
				<class type="func"> Smoking cessation agent</class>
				<class type="chem"> Nicotine receptor agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2250">
				<sec_title>Action:</sec_title>
				<para>Partial agonist for nicotine receptors; partially activates receptors to help curb cravings; occupies receptors to prevent nicotine binding</para>
			</section>
			<section type="uses" id="sidelem4x2255">
				<sec_title>Uses:</sec_title>
				<para>Smoking deterrent</para>
			</section>
			<section type="contra" id="sidelem4x2260">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, eating disorders</para>
				<section type="none" id="sidelem4x2265">
					<section type="none" id="sidelem4x2266">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;18 yr, geriatric patients, renal disease, recent MI, angioedema</para>
						<para>
							<bbw>Bipolar disorder, depression, schizophrenia, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2281">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2284">
					<section type="none" id="sidelem4x2285">
						<sec_title>Smoking cessation</sec_title>
						<section type="none" id="sidelem4x2293">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2293">
									<item>
										<label>•</label>
										<para> therapy should begin 1 wk before smoking stop date (i.e., take product plus tobacco for 7 days); titrate for 1 wk; days 1 through 3, 0.5 mg/day; days 4 through 7, 0.5 mg bid; day 8 through end of treatment, 1 mg bid; treatment is for 12 wk and may be repeated for another 12 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2297">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x2305">
							<label>•</label>
							<sec_title>Adult<route> PO CCr ≤50 ml/min, titrate to max 0.5 mg bid</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2308">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.5, 1 mg; Chantix continuing month PAK; Chantix starting month PAK</para>
					</section>
					<section type="none" id="sidelem4x2313">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2317">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew tabs</para>
								</item>
								<item>
									<label>•</label>
									<para>Increased fluids, bulk in diet if constipation occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>After eating with a full glass of water</para>
								</item>
								<item>
									<label>•</label>
									<para>Sugarless gum, hard candy, or frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2338">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2341">
					<section type="none" id="sidelem4x2342">
						<sec_title>CNS:</sec_title>
						<para> Headache, agitation, dizziness, insomnia, abnormal dreams, fatigue, malaise, behavior changes, depression, <emphasis style="bold">suicidal ideation,</emphasis> amnesia, hallucinations, hostility, mania, psychosis, tremors</para>
					</section>
					<section type="none" id="sidelem4x2350">
						<sec_title>CV:</sec_title>
						<para> Dysrhythmias, hypo/hypertension, palpitations, tachycardia, angina, <emphasis style="bold">MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2357">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision,</emphasis> tinnitus</para>
					</section>
					<section type="none" id="sidelem4x2365">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> anorexia, <emphasis style="italic">dry mouth,</emphasis> increased/decreased appetite, <emphasis style="italic">constipation,</emphasis> flatulence, GERD</para>
					</section>
					<section type="none" id="sidelem4x2379">
						<sec_title>GU:</sec_title>
						<para> Erectile dysfunction, urinary frequency, menstrual irregularities</para>
					</section>
					<section type="none" id="sidelem4x2384">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, <emphasis style="bold">angioedema, Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2391">
						<sec_title>MISC:</sec_title>
						<para> Weight loss or gain</para>
					</section>
					<section type="none" id="sidelem4x2396">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, rhinorrhea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2401">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Elimination half-life 24 hr; metabolism minimal; 93% excreted unchanged in urine; steady state 4 days, onset 4 days, peak 3-4 hr</para>
			</section>
			<section type="considerations" id="sidelem4x2406">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2409">
					<section type="none" id="sidelem4x2410">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2418">
							<label>•</label>
							<sec_title>Smoking history</sec_title>
							<para>
								<list id="lidelem4x2418">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Smoking history:</emphasis> motivation for smoking cessation, years used, amount each day; smoking cessation after 12 wk; if progress not made, product may be used for additional 12 wk</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2422">
								<item>
									<label>•</label>
									<para>Renal function in geriatric patients; cardiac status in cardiac disease
<bbw>Neuropsychiatric symptoms: mood, sensorium, affect; behavior changes, agitation, depression, suicidal ideation; suicide has occurred; possible worsening of depression, schizophrenia, bipolar disorder</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2436">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2440">
								<item>
									<label>•</label>
									<para>Therapeutic response: smoking cessation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2446">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2450">
								<item>
									<label>•</label>
									<para>That treatment for smoking cessation lasts 12 wk and that another 12 wk may be required</para>
								</item>
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities requiring alertness; blurred vision may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To set a date to quit smoking and to initiate treatment 1 wk before that date</para>
								</item>
								<item>
									<label>•</label>
									<para>How to titrate product</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use with nicotine patches unless directed by prescriber; may increase B/P</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy planned or suspected</para>
								</item>
								<item>
									<label>•</label>
									<para>About common side effects to be expected
<bbw>To notify prescriber immediately of change in thought/behavior (suicidal ideation, hostility, depression), stop product</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>vasopressin (Rx)</mono_name>
			<info>
				<pronunciation>(vay-soe-press′in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x25000">
						<country code="CAN">Pressyn </country>
					</tradename>
				</tradenames>
				<class type="func"> Pituitary hormone</class>
				<class type="chem"> Lysine vasopressin</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2512">
				<sec_title>Action:</sec_title>
				<para>Promotes the reabsorption of water via action on the renal tubular epithelium; causes vasoconstriction</para>
			</section>
			<section type="uses" id="sidelem4x2517">
				<sec_title>Uses:</sec_title>
				<para>Diabetes insipidus (nonnephrogenic/nonpsychogenic), abdominal distention postoperatively, bleeding esophageal varices</para>
			</section>
			<section type="contra" id="sidelem4x2522">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, chronic nephritis</para>
				<section type="none" id="sidelem4x2527">
					<section type="none" id="sidelem4x2528">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, CAD, asthma, vascular/renal disease, migraines, seizures</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2533">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2536">
					<section type="none" id="sidelem4x2537">
						<sec_title>Diabetes insipidus</sec_title>
						<section type="none" id="sidelem4x2545">
							<label>•</label>
							<sec_title>Adult<route> IM/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x2545">
									<item>
										<label>•</label>
										<para> 5-10 units bid-qid as needed;  0.0005 units/kg/hr (0.05 milliunit/kg/hr), double dose q30min as needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2555">
							<label>•</label>
							<sec_title>Child<route> IM/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x2555">
									<item>
										<label>•</label>
										<para> 2.5-10 units bid-qid as needed;  1.25-2.5 units q2-3days (Pitressin Tannate) for chronic therapy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2562">
						<sec_title>Abdominal distention</sec_title>
						<section type="none" id="sidelem4x2570">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x2570">
									<item>
										<label>•</label>
										<para> 5 units, then q3-4hr, increasing to 10 units if needed (aqueous)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2574">
						<sec_title>Available forms:</sec_title>
						<para> sol for inj 20 units/ml</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2579">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2582">
					<section type="none" id="sidelem4x2583">
						<sec_title>CNS:</sec_title>
						<para> Drowsiness, headache, lethargy, flushing, vertigo</para>
					</section>
					<section type="none" id="sidelem4x2588">
						<sec_title>CV:</sec_title>
						<para> Increased B/P, dysrhythmias, <emphasis style="bold">cardiac arrest, shock,</emphasis> chest pain, <emphasis style="bold">MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2598">
						<sec_title>EENT:</sec_title>
						<para> Nasal irritation, congestion, rhinitis</para>
					</section>
					<section type="none" id="sidelem4x2603">
						<sec_title>GI:</sec_title>
						<para> Nausea, heartburn, cramps, vomiting, flatus</para>
					</section>
					<section type="none" id="sidelem4x2608">
						<sec_title>GU:</sec_title>
						<para> Vulval pain, uterine cramping</para>
					</section>
					<section type="none" id="sidelem4x2613">
						<sec_title>MISC:</sec_title>
						<para> Tremors, sweating, vertigo, urticaria, bronchial constriction</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2618">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x2621">
					<section type="none" id="sidelem4x2622">
						<sec_title>Nasal:</sec_title>
						<para> Onset 1 hr; duration 3-8 hr; half-life 15 min; metabolized in liver, kidneys; excreted in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2627">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> antidiuretic effect—tricyclics, carBAMazepine, chloropromide, fludrocortisone, clofibrate, urea</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antidiuretic effect—lithium, demeclocycline</para>
			</section>
			<section type="considerations" id="sidelem4x2638">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2641">
					<section type="none" id="sidelem4x2642">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2647">
								<item>
									<label>•</label>
									<para>Pulse, B/P when giving product IV or IM</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2652">
								<item>
									<label>•</label>
									<para>I&amp;O ratio, weight daily; fluid/electrolyte balance; check for edema in extremities; if water retention is severe, diuretic may be prescribed</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2660">
							<label>•</label>
							<sec_title>Water intoxication<route> lethargy, behavioral changes, disorientation, neuromuscular excitability</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2663">
								<item>
									<label>•</label>
									<para>Small doses may precipitate coronary adverse effects; keep emergency equipment nearby</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2668">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2672">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of severe thirst, decreased urine output, osmolality</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2678">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2682">
								<item>
									<label>•</label>
									<para>To measure and record I&amp;O</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, all OTC medications unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>vedolizumab</mono_name>
			<info>
				<pronunciation>(ve′-doe-liz′ue-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x26980">Entyvio</tradename>
				</tradenames>
				<class type="func"> Immunosuppressive, biologic response modifiers</class>
			</info>
			<section type="actions" id="sidelem4x2704">
				<sec_title>Action:</sec_title>
				<para> A specific integrin receptor antagonist that inhibits the migration of specific memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. The action reduces the chronic inflammatory process present in both ulcerative colitis and Crohn’s disease</para>
			</section>
			<section type="uses" id="sidelem4x2709">
				<sec_title>Uses:</sec_title>
				<para> For moderately to severely active ulcerative colitis/Crohn’s disease to reduce signs and symptoms, and to induce and maintain clinical remission in patients who have an inadequate response to conventional therapy</para>
			</section>
			<section type="contra" id="sidelem4x2714">
				<sec_title>Contraindications:</sec_title>
				<para> Hypersensitivity</para>
				<section type="none" id="sidelem4x2719">
					<section type="none" id="sidelem4x2720">
						<sec_title>Precautions:</sec_title>
						<para> Hepatic disease, infections, progressive multifocal leukoencephalopathy (PML), pregnancy (B), breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2725">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2733">
					<label>•</label>
					<sec_title>Adults<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x2733">
							<item>
								<label>•</label>
								<para> INFUSION 300 mg 30 min at weeks 0, 2, and 6 as induction therapy, then 300 mg q8wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2737">
					<section type="none" id="sidelem4x2738">
						<sec_title>Available forms:</sec_title>
						<para> Powder for injection 300 mg</para>
					</section>
					<section type="none" id="sidelem4x2743">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2747">
								<item>
									<label>•</label>
									<para>Full response is usually observed by 6 wk; those who do not respond by week 14 are unlikely to respond</para>
								</item>
								<item>
									<label>•</label>
									<para>Give as IV infusion only, do not use as an IV push or bolus</para>
								</item>
								<item>
									<label>•</label>
									<para>Make sure all immunizations are up to date</para>
								</item>
								<item>
									<label>•</label>
									<para>Reconstitute with 4.8 ml of sterile water for injection, using a syringe with a 21- to 25-gauge needle</para>
								</item>
								<item>
									<label>•</label>
									<para>Insert the syringe needle into the vial and direct the stream of sterile water for injection to the glass wall of the vial, gently swirl the solution for 15 sec, do not shake</para>
								</item>
								<item>
									<label>•</label>
									<para>Allow the solution to stand for up to 20 min at room temperature to allow for reconstitution and for any foam to settle</para>
								</item>
								<item>
									<label>•</label>
									<para>Once dissolved, product should be clear or opalescent, colorless to light brownish yellow, and free of visible particulates. Discard if discolored or if foreign particles are present</para>
								</item>
								<item>
									<label>•</label>
									<para>Before withdrawing solution from vial, gently invert vial 3 times. Withdraw 5 ml (300 mg) of reconstructed product using a 21- to 25-gauge needle. Discard remaining product</para>
								</item>
								<item>
									<label>•</label>
									<para>Add the 5 ml (300 mg) of reconstituted product to 250 ml of sterile 0.9% sodium chloride and gently mix infusion bag. Do not mix with other medications. Administer solution as soon as possible; if necessary, may be stored for up to 4 hr refrigerated, do not freeze. Infuse over 30 min; after infusion, flush line with 30 ml of sterile 0.9% sodium chloride injection. Discard any unused infusion solution</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2793">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2796">
					<section type="none" id="sidelem4x2797">
						<sec_title>CNS:</sec_title>
						<para> Headache, fatigue, dizziness</para>
					</section>
					<section type="none" id="sidelem4x2802">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x2807">
						<sec_title>MISC:</sec_title>
						<para> Rash, pruritus, infusion-related reactions</para>
					</section>
					<section type="none" id="sidelem4x2812">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, back pain</para>
					</section>
					<section type="none" id="sidelem4x2817">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, progressive multifocal leukoencephalopathy (PML)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2824">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x2827">
					<section type="none" id="sidelem4x2828">
						<sec_title>Increase:</sec_title>
						<para> infection risk—immunosuppressives, natalizumab, antineoplastics</para>
						<para>
							<emphasis alert="lifethreat">Do not use with tumor necrosis factor (TNF) modifiers</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x2836">
						<sec_title>Decrease:</sec_title>
						<para> immune response—vaccines, toxoids</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2841">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2844">
					<section type="none" id="sidelem4x2845">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2853">
							<label>•</label>
							<sec_title>Ulcerative colitis/Crohn’s disease</sec_title>
							<para>
								<list id="lidelem4x2853">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ulcerative colitis/Crohn’s disease:</emphasis> Monitor symptoms before and after treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2860">
							<label>•</label>
							<sec_title>Liver dysfunction<route> Elevated hepatic enzymes, jaundice, malaise, nausea, vomiting, abdominal pain, and anorexia are predictive of severe liver injury that may be fatal or may require a liver transplant in some patients; if hepatic dysfunction is suspected, discontinue</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2866">
							<label>•</label>
							<sec_title>Tuberculosis (TB) latent/active<route> Obtain TB skin test both before and during treatment. Do not give in active infection like influenza or sepsis</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2872">
							<label>•</label>
							<sec_title>Progressive multifocal leukoencephalopathy (PML)<route> Increased weakness on one side of the body or clumsiness of limbs, visual disturbance, and changes in thinking, memory, and orientation leading to confusion and personality changes; severe disability or death can come over weeks or months</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2875">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2879">
								<item>
									<label>•</label>
									<para>Therapeutic response: lessening of ulcerative colitis and Crohn’s disease</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2885">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2889">
								<item>
									<label>•</label>
									<para>About the symptoms of infection and to report to health care provider immediately</para>
								</item>
								<item>
									<label>•</label>
									<para>To report planned or suspected pregnancy, or if breastfeeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active" ha="yes">
			<mono_name> vemurafenib</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x29050">Zelboraf</tradename>
				</tradenames>
				<class type="func"> Biologic response modifiers; signal transduction inhibitors (STIs)</class>
			</info>
			<section type="actions" id="sidelem4x2911">
				<sec_title>Action:</sec_title>
				<para>Inhibitor of some mutated forms of BRAF serine threonine kinase, thereby blocking cellular proliferation in melanoma cells with the mutation; inhibits other kinases including CRAF, ARAF, wild-type BRAF, SRMA, ACK1, MAP4H5, and FGR; potent adenosine triphosphate-competitice inhibitor of RAFs, with a modest preference for mutant BRAF and CRAF compared with wild-type BRAF</para>
			</section>
			<section type="uses" id="sidelem4x2916">
				<sec_title>Uses:</sec_title>
				<para>Unresectable or metastatic malignant melanoma with V600E mutation of the BRAF gene</para>
				<section type="none" id="sidelem4x2921">
					<section type="none" id="sidelem4x2922">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="D">D</preg>), breastfeeding, children, infants, neonates, hepatic disease, QT prolongation, secondary malignancy, torsades de pointes, hypokalemia, hypomagnesia, sunlight exposure</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2927">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2935">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2935">
							<item>
								<label>•</label>
								<para> 960 mg (4 tabs) bid about q12hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2939">
					<section type="none" id="sidelem4x2940">
						<sec_title>Dose adjustments for toxicity due to symptomatic adverse reactions or QTc prolongation</sec_title>
						<para>
							<emphasis alert="lifethreat">Grade 1 or tolerable grade 2 adverse events: no dosage change; intolerable grade 2 or grade 3 adverse events (1st episode): interrupt treatment until toxicity resolves to grade ≤1, when resuming, reduce dosage to 720 mg (3 tabs) bid; intolerable grade 2 or grade 3 adverse events (2nd episode): interrupt treatment until toxicity resolves to grade ≤1, when resuming, reduce dose to 480 mg (2 tabs) bid; intolerable grade 2 or grade 3 adverse events (3rd episode) discontinue treatment permanently; grade 4 adverse events (1st episode): discontinue permanently or interrupt until toxicity resolves to grade ≤1, when resuming, reduce dose to 480 mg (2 tabs) bid; grade 4 adverse events (2nd episode): discontinue permanently</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x2946">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 240 mg</para>
					</section>
					<section type="none" id="sidelem4x2951">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2955">
								<item>
									<label>•</label>
									<para>Continue until disease progresses or unacceptable toxicity occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>Missed doses can be taken up to 4 hr before the next dose is due; take about 12 hr apart, take without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Swallow whole with a full glass of water; do not crush or chew</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature in original container</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2976">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2979">
					<section type="none" id="sidelem4x2980">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, fever, asthenia, headache, dizziness, peripheral neuropathy, muscle paralysis</para>
					</section>
					<section type="none" id="sidelem4x2985">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">QT prolongation, atrial fibrillation,</emphasis> peripheral edema, hypotension</para>
					</section>
					<section type="none" id="sidelem4x2993">
						<sec_title>EENT:</sec_title>
						<para> Uveitis, blurred vision, iritis, photophobia</para>
					</section>
					<section type="none" id="sidelem4x2998">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea, vomiting, constipation, dysgeusia, decreased appetite, weight loss</para>
					</section>
					<section type="none" id="sidelem4x3003">
						<sec_title>INTEG:</sec_title>
						<para> Alopecia, pruritus, hyperkeratosis, maculopapular rash, actinic keratosis, xerosis/dry skin, papular rash, palmar-plantar erythrodysesthesia (hand and foot syndrome), photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x3008">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, myalgias, extremity pain, musculoskeletal pain, back pain, arthritis</para>
					</section>
					<section type="none" id="sidelem4x3013">
						<sec_title>RESP:</sec_title>
						<para> Cough</para>
					</section>
					<section type="none" id="sidelem4x3018">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Secondary malignancy, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3025">
				<sec_title>Pharmacokinetics</sec_title>
				<para>&gt;99% protein binding (albumin and alpha-1 acid glycoprotein) an inhibitor of CYP1A2, 2A6, 2C9, 2C19, 2D6, 3A4/5 CYP1A2 inhibitor, a weak CYP2D6 inhibitor, and a CYP3A4 inducer; elimination 94% in feces, 1% in urine, half-life 57 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3030">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> vemurafenib effect—CYP3A4/CYP1A2 inhibitors (enoxacin, cimetidine, delavirdine, indinavir, isoniazid, itraconazole, dalfopristin, quinupristin, tipranavir)</para>
				<para>
					<emphasis alert="nurse">Increase: QT prolongation, torsades de pointes—arsenic trioxide, certain phenothiazines (chlorproMAZINE, mesoridazine, thioridazine), grepafloxacin, levomethadyl, pentamidine, probucol, sparfloxacin, troleandomycin, class IA antiarrhythmics (disopyramide, procainamide, quiNIDine), class III antiarrhythmics (amiodarone, dofetilide, ibutilide, sotalol), clarithromycin, ziprasidone, pimozide, haloperidol, halofantrine, quiNIDine, chloroquine, dronedarone, droperidol, erythromycin, methadone, posaconazole, propafenone, saquinavir, abarelix, amoxapine, apomorphine, asenapine, β-agonists, ofloxacin, eribulin, ezogabine, flecainide, gatifloxacin, gemifloxacin, halogenated anesthetics, iloperidone, levofloxacin, local anesthetics, magnesium sulfate, potassium sulfate, sodium, maprotiline, moxifloxacin, nilotinib, norfloxacin, ciprofloxacin, OLANZapine, paliperidone, some phenothiazines (fluPHENAZine, perphenazine, prochlorperazine, trifluoperazine), telavancin, tetrabenazine, tricyclic antidepressants, venlafaxine, vorinostat, citalopram, alfuzosin, cloZAPine, cyclobenzaprine, dolasetron, palonosetron, QUEtiapine, rilpivirine, SUNItinib, tacrolimus, vardenafil, indacaterol, dasatinib, fluconazole, lapatinib, lopinavir/ritonavir, mefloquine, octreotide, ondansetron, ranolazine, risperiDONE, telithromycin, vemurafenib</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> vemurafenib effect—CYP3A4 inducers (rifampin, barbiturates, carBAMazepine, phenytoin, erythromycin, ketoconazole, fluvoxaMINE, alcohol, etravirine, ritonavir, bexarotene, rifabutin, OXcarbazepine, nevirapine, modafinil, metyrapone)</para>
				<section type="none" id="sidelem4x3046">
					<section type="none" id="sidelem4x3047">
						<sec_title>Drug/Lab Test:</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum creatinine, LFTs, alkaline phosphatase, bilirubin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3054">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3057">
					<section type="none" id="sidelem4x3058">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3066">
							<label>•</label>
							<sec_title>Hepatic disease</sec_title>
							<para>
								<list id="lidelem4x3066">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hepatic disease:</emphasis> Liver function test (LFT) abnormalities, altered bilirubin levels, may occur; monitor LFTs and bilirubin levels before treatment, then monthly; more frequent testing is needed in those with grade 2 or greater toxicities; laboratory alterations should be managed with dose reduction, treatment interruption, or discontinuation</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3071">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation: has been reported with the use of this product; therefore, should be avoided in patients with QT prolongation; monitor ECG and electrolytes in those with congestive heart failure, bradycardia, electrolyte imbalance (hypokalemia, hypomagnesemia), or those who are taking concomitant medications known to prolong the QT interval; treatment interruption, dosage adjustment, treatment discontinuation may be needed in those who develop QT prolongation</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3077">
								<item>
									<para>
										<emphasis alert="nurse">Pregnancy/breastfeeding: Identify if pregnancy is planned or suspected, pregnancy (D); avoid breastfeeding</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3082">
								<item>
									<label>•</label>
									<para>Serum electrolytes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3087">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3091">
								<item>
									<label>•</label>
									<para>Decreased spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3097">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3102">
								<item>
									<label>•</label>
									<para>That missed doses can be taken up to 4 hr before the next dose is due to maintain the twice-daily regimen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3108">
								<item>
									<para>
										<emphasis alert="nurse">Teach patient to use reliable contraception; both women and men of childbearing age should use adequate contraceptive methods during therapy and for at least 90 days after completing treatment, pregnancy (D)</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>venlafaxine (Rx)</mono_name>
			<info>
				<pronunciation>(ven-la-fax′een)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x31181">
						<country code="CAN">Effexor </country>
					</tradename>
					<tradename id="tnidelem4x31180">Effexor XR</tradename>
				</tradenames>
				<class type="func"> Antidepressant—SNRI</class>
				<class type="chem"> SNRI</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3131">
				<sec_title>Action:</sec_title>
				<para>Potent inhibitor of neuronal serotonin and norepinephrine uptake, weak inhibitor of dopamine; no muscarinic, histaminergic, or α-adrenergic receptors in vitro</para>
			</section>
			<section type="uses" id="sidelem4x3136">
				<sec_title>Uses:</sec_title>
				<para>Prevention/treatment of major depression; depression at the end of life; long-term treatment of general anxiety disorder, panic disorder, social anxiety disorder (Effexor XR only)</para>
				<section type="none" id="sidelem4x3141">
					<section type="none" id="sidelem4x3142">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hot flashes, premenstrual dysphoric disorder (PMDD), headache, neuropathic pain, fibromyalgia, diabetic neuropathy</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3147">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x3152">
					<section type="none" id="sidelem4x3153">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, mania, hypertension, seizure disorder, recent MI, cardiac/renal/hepatic disease, eosinophilic pneumonia, desvenlafaxine hypersensitivity, bipolar disorder, interstitial lung disease</para>
						<para>
							<bbw>Children, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3168">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3171">
					<section type="none" id="sidelem4x3172">
						<sec_title>Depression</sec_title>
						<section type="none" id="sidelem4x3180">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3180">
									<item>
										<label>•</label>
										<para> 75 mg/day in 2-3 divided doses; taken with food, may be increased to 150 mg/day; if needed, may be further increased to 225 mg/day; increments of 75 mg/day at intervals of ≥4 days; some hospitalized patients may require up to 375 mg/day in 3 divided doses;  37.5-75 mg PO daily, max 225 mg/day; give XR daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3187">
						<sec_title>Anxiety disorders</sec_title>
						<section type="none" id="sidelem4x3195">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3195">
									<item>
										<label>•</label>
										<para> 75 mg/day or 37.5 mg/day × 4-7 days initially, max 225 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3199">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x3207">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 10-70 ml/min, reduce dose by 25%-50%; CCr &lt;10 ml/min, reduce dose by 50%</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3210">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x3218">
							<label>•</label>
							<sec_title>Adult<route> PO Moderate impairment, 50% of dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3221">
						<sec_title>Hot flashes (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3229">
							<label>•</label>
							<sec_title>Adult (male, prostate cancer)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3229">
									<item>
										<label>•</label>
										<para> 12.5 mg bid × 4 wk; females 37.5-75 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3233">
						<sec_title>Neuropathic pain, diabetic neuropathy, headache, fibromyalgia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3241">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3241">
									<item>
										<label>•</label>
										<para> 37.5-75 mg/day, max 75 mg bid (regular rel) or 150 mg/day (ext rel)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3245">
						<sec_title>Premenstrual dysphoric disorder (PMDD) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3253">
							<label>•</label>
							<sec_title>Adult female<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3253">
									<item>
										<label>•</label>
										<para> 50-200 mg/day, start at 50 mg/day for 1st cycle, titrate upward</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3257">
						<sec_title>Available forms:</sec_title>
						<para> Tabs scored 25, 37.5, 50, 75, 100 mg; ext rel cap (Effexor XR) 37.5, 75, 150 mg</para>
					</section>
					<section type="none" id="sidelem4x3262">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3266">
								<item>
									<label>•</label>
									<para>With food, milk for GI symptoms; do not crush, chew caps; caps can be opened and contents sprinkled on applesauce, given with full glass of water</para>
								</item>
								<item>
									<label>•</label>
									<para>Sugarless gum, hard candy, frequent sips of water for dry mouth</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid use with CNS depressants</para>
								</item>
								<item>
									<label>•</label>
									<para>Give in small amounts because of suicide potential, especially at beginning of therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3292">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3295">
					<section type="none" id="sidelem4x3296">
						<sec_title>CNS:</sec_title>
						<para> Emotional lability, <emphasis style="italic">dizziness, weakness,</emphasis> apathy, ataxia, headache, tremors, hypertonia, euphoria, hallucinations, hostility, insomnia, anxiety, <emphasis style="bold">suicidal ideation in children/adolescents, seizures, neuroleptic-malignant-syndrome–like reaction</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3306">
						<sec_title>CV:</sec_title>
						<para> Angina pectoris, hypertension, <emphasis style="bold">tachycardia, change in QTcinterval,</emphasis> increased cholesterol, extrasystoles, syncope</para>
					</section>
					<section type="none" id="sidelem4x3314">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Abnormal vision,</emphasis> taste, <emphasis style="italic">ear pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3324">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Dysphagia, eructation, nausea,</emphasis> anorexia, dry mouth, colitis, gastritis, gingivitis, <emphasis style="italic">constipation,</emphasis> stomatitis, stomach and mouth ulceration</para>
					</section>
					<section type="none" id="sidelem4x3335">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Anorgasmia,</emphasis> abnormal ejaculation, urinary frequency, decreased libido, impotence, menstrual changes, <emphasis style="italic">impaired urination</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3345">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukocytosis, leukopenia, abnormal bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3352">
						<sec_title>INTEG:</sec_title>
						<para> Ecchymosis, brittle nails, dry skin, photosensitivity, sweating, <emphasis style="bold">Stevens-Johnson syndrome; angioedema (ext rel)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3359">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Peripheral edema, weight loss,</emphasis> edema, glycosuria, hyperlipemia, hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x3367">
						<sec_title>MS:</sec_title>
						<para> Arthritis, bone pain, tenosynovitis, arthralgia</para>
					</section>
					<section type="none" id="sidelem4x3372">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Bronchitis, dyspnea,</emphasis> cough</para>
					</section>
					<section type="none" id="sidelem4x3380">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Neonatal abstinence syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3387">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed; extensively metabolized in liver by CYP2D6 to active metabolite; 87% of product recovered in urine; 27% protein binding; half-life 5, 11 hr (active metabolite), respectively</para>
			</section>
			<section type="interactions" id="sidelem4x3392">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Hyperthermia, rigidity, rapid fluctuations of vital signs, mental status changes, neuroleptic malignant syndrome: MAOIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—salicylates, NSAIDs, platelet inhibitors, anticoagulants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> venlafaxine effect—cimetidine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, opioids, antihistamines, sedative/hypnotics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of cloZAPine, desipramine, haloperidol, warfarin</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome—sibutramine, SUMAtriptan, traZODone, traMADol, SSRIs, serotonin receptor agonist, linezolid, methylene blue, tryptophan</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of indinavir</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> venlafaxine effect—cyproheptadine</para>
				<section type="none" id="sidelem4x3427">
					<section type="none" id="sidelem4x3428">
						<sec_title>Drug/Herb</sec_title>
						<section type="none" id="sidelem4x3436">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> St. John’s wort, tryptophan</route></sec_title>
						</section>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava, valerian</para>
					</section>
					<section type="none" id="sidelem4x3443">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> alk phos, bilirubin, AST, ALT, BUN, creatinine, serum cholesterol, CPK, LDH</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> amphetamines, phencyclidine</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3454">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3457">
					<section type="none" id="sidelem4x3458">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Mental status: mood, sensorium, affect, increase in psychiatric symptoms; depression, panic; assess for suicidal ideation in children/adolescents</bbw>
						</para>
						<para>
							<list id="lidelem4x3472">
								<item>
									<label>•</label>
									<para>B/P lying, standing; pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; take VS q4hr in patients with CV disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3478">
								<item>
									<para>
										<emphasis alert="nurse">Bleeding: GI, ecchymosis, epistaxis, hematomas, petechiae, hemorrhage</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3483">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, differential, leukocytes, cardiac enzymes if patient is receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3488">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3493">
								<item>
									<label>•</label>
									<para>Weight weekly; weight loss or gain; appetite may increase; peripheral edema may occur; monitor cholesterol</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3501">
							<label>•</label>
							<sec_title>Withdrawal symptoms</sec_title>
							<para>
								<list id="lidelem4x3501">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Withdrawal symptoms:</emphasis> flulike symptoms, headache, nervousness, agitation, nausea, vomiting, muscle pain, weakness; not usual unless product is discontinued abruptly</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3506">
								<item>
									<para>
										<emphasis alert="nurse">Serotonin syndrome, neuroleptic malignant syndrome: increased heart rate, shivering, sweating, dilated pupils, tremors, high B/P, hyperthermia, headache, confusion; if these occur, stop product, administer serotonin antagonist if needed; usually worse if given with linezolid, methylene blue, tryptophan</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3511">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy because drowsiness, dizziness occur</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3516">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3520">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression, anxiety; increased well-being</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3526">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3531">
								<item>
									<label>•</label>
									<para>To notify prescriber of rash, hives, allergic reactions, bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3536">
								<item>
									<label>•</label>
									<para>To use with caution when driving, performing other activities requiring alertness because of drowsiness, dizziness, blurred vision
<bbw>That worsening of symptoms, suicidal thoughts/behaviors may occur in children/young adults, discuss with family members</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3550">
								<item>
									<label>•</label>
									<para>To avoid alcohol ingestion</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3555">
								<item>
									<label>•</label>
									<para>Not to discontinue medication abruptly after long-term use; may cause nausea, headache, malaise, taper over 14 days</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3560">
								<item>
									<label>•</label>
									<para>To wear sunscreen or large hat because photosensitivity occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3568">
							<label>•</label>
							<sec_title>
								<route>To avoid pregnancy or breastfeeding while taking this product; birth defects have occurred when used in the 3rd trimester</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3571">
								<item>
									<label>•</label>
									<para>To monitor B/P with hypertension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3579">
							<label>•</label>
							<sec_title>Serotonin syndrome, neuroleptic malignant syndrome<route> Advise patient to report immediately shivering, sweating, tremors, fever, dilated pupils</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x3582">
								<item>
									<label>•</label>
									<para>To take as prescribed, contents of capsule may be sprinkled on applesauce if unable to swallow whole</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active">
			<mono_name>verapamil (Rx)</mono_name>
			<info>
				<pronunciation>(ver-ap′a-mill)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x35978">
						<country code="CAN">Apo-Verap </country>
					</tradename>
					<tradename id="tnidelem4x35977">Calan</tradename>
					<tradename id="tnidelem4x35976">Calan SR</tradename>
					<tradename id="tnidelem4x35975">
						<country code="CAN">Chronovera </country>
					</tradename>
					<tradename id="tnidelem4x35974">
						<country code="CAN">Covera </country>
					</tradename>
					<tradename id="tnidelem4x35973">Isoptin SR</tradename>
					<tradename id="tnidelem4x35972">
						<country code="CAN">Tarka </country>
					</tradename>
					<tradename id="tnidelem4x35971">Verelan</tradename>
					<tradename id="tnidelem4x35970">Verelan PM</tradename>
				</tradenames>
				<class type="func"> Calcium channel blocker; antihypertensive; antianginal, antidysrhythmic (class IV)</class>
				<class type="chem"> Diphenylalkylamine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3619">
				<sec_title>Action:</sec_title>
				<para>Inhibits calcium ion influx across cell membrane during cardiac depolarization; produces relaxation of coronary vascular smooth muscle; dilates coronary arteries; decreases SA/AV node conduction; dilates peripheral arteries</para>
			</section>
			<section type="uses" id="sidelem4x3624">
				<sec_title>Uses:</sec_title>
				<para>Chronic stable, vasospastic, unstable angina; dysrhythmias, hypertension, supraventricular tachycardia, atrial flutter or fibrillation</para>
				<section type="none" id="sidelem4x3629">
					<section type="none" id="sidelem4x3630">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Prevention of migraine headaches, claudication, mania</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3635">
				<sec_title>Contraindications:</sec_title>
				<para>Sick sinus syndrome, 2nd-/3rd-degree heart block, hypotension &lt;90 mm Hg systolic, cardiogenic shock, severe CHF, Lown-Ganong-Levine syndrome, Wolff-Parkinson-White syndrome</para>
				<section type="none" id="sidelem4x3640">
					<section type="none" id="sidelem4x3641">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, CHF, hypotension, hepatic injury, renal disease, concomitant β-blocker therapy</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3646">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3649">
					<section type="none" id="sidelem4x3650">
						<sec_title>Angina</sec_title>
						<section type="none" id="sidelem4x3658">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3658">
									<item>
										<label>•</label>
										<para> 80-120 mg tid, increase weekly, max 480 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3662">
						<sec_title>Dysrhythmias</sec_title>
						<section type="none" id="sidelem4x3670">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3670">
									<item>
										<label>•</label>
										<para> 240-480 mg/day in 3-4 divided doses in digitalized patients</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3677">
							<label>•</label>
							<sec_title>Adult<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x3677">
									<item>
										<label>•</label>
										<para> 5-10 mg (0.075-0.15 mg/kg) over 2 min, may repeat 10 mg (0.15 mg/kg) <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr after 1st dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3690">
							<label>•</label>
							<sec_title>Child 1-15 yr<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x3690">
									<item>
										<label>•</label>
										<para> 0.1-0.3 mg/kg over ≥2 min, repeat in 30 min, max 5 mg in single dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3697">
							<label>•</label>
							<sec_title>Child 0-1 yr<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x3697">
									<item>
										<label>•</label>
										<para> 0.1-0.2 mg/kg over ≥2 min, may repeat after 30 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3701">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x3709">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3709">
									<item>
										<label>•</label>
										<para> 80 mg tid, may titrate upward;  120-240 mg/day as single dose, may increase to 240-480 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3716">
						<sec_title>Hepatic disease/geriatric patients/ compromised ventricular function</sec_title>
						<section type="none" id="sidelem4x3724">
							<label>•</label>
							<sec_title>Adult<route> PO 40 mg tid initially, increase as tolerated</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3727">
						<sec_title>Claudication due to PVD (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3735">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3735">
									<item>
										<label>•</label>
										<para> 120-480 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3739">
						<sec_title>Mania (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3747">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3747">
									<item>
										<label>•</label>
										<para> 160-320 mg/day in divided doses, may be given with lithium</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3751">
						<sec_title>Migraine prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3759">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3759">
									<item>
										<label>•</label>
										<para> 80 mg tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3763">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 40, 80, 120 mg; ext rel tabs 120, 180, 240 mg; inj 2.5 mg/ml in ampules, syringes, vials; ext rel caps 100, 200, 240, 300 mg</para>
					</section>
					<section type="none" id="sidelem4x3768">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3771">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x3779">
								<label>•</label>
								<sec_title>Reg rel</sec_title>
								<para>
									<list id="lidelem4x3779">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Reg rel:</emphasis> Give without regard to food</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x3783">
							<sec_title>Ext rel route</sec_title>
							<para>
								<list id="lidelem4x3787">
									<item>
										<label>•</label>
										<para>Do not crush or chew ext rel products; caps may be opened and contents sprinkled on food; do not dissolve chew cap contents</para>
									</item>
									<item>
										<label>•</label>
										<para>Before meals, at bedtime; give ext rel product with food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3798">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x3803">
									<item>
										<label>•</label>
										<para>Undiluted through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock of compatible sol; give over 2 min or 3 min for geriatric patients, with continuous ECG and B/P monitoring, discard unused solution</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x3814">
								<label>•</label>
								<sec_title>
									<route>Do not use IV with IV β-blockers, may cause AV nodal blockade</route>
								</sec_title>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, amikacin, argatroban, ascorbic acid, atracurium, atropine, aztreonam, bivalirudin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, ceFAZolin, cefonicid, cefotaxime, cefoTEtan, cefOXitin, ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, ciprofloxacin, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin hydrochloride, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, ifosfamide, imipenem/cilastatin, inamrinone, insulin, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, metaraminol, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, miconazole, midazolam, milrinone, mitoXANtrone, morphine, multivitamins, nalbuphine, naloxone, nesiritide, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, papaverine, PEMEtrexed, penicillin G, pentamidine, pentazocine, phentolamine, phenylephrine, phytonadione, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine, promethazine, propranolol, protamine, pyridoxime, quinupristin/dalfopristin, ranitidine, rocuronium, sodium acetate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, ticarcillin/clavulanate, tirofiban, tobramycin, tolazoline, trimethaphan, urokinase, vancomycin, vasopressin, vecuronium, vinCRIStine, vinorelbine, voriconazole</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3821">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3824">
					<section type="none" id="sidelem4x3825">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, drowsiness,</emphasis> dizziness, anxiety, depression, weakness, insomnia, confusion, lightheadedness, asthenia, fatigue</para>
					</section>
					<section type="none" id="sidelem4x3833">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Edema,</emphasis><emphasis style="bold">CHF,</emphasis> bradycardia, hypotension, palpitations, AV block, <emphasis style="bold">dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3845">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> diarrhea, gastric upset, <emphasis style="italic">constipation,</emphasis> increased LFTs</para>
					</section>
					<section type="none" id="sidelem4x3856">
						<sec_title>GU:</sec_title>
						<para> Impotence, gynecomastia, nocturia, polyuria</para>
					</section>
					<section type="none" id="sidelem4x3861">
						<sec_title>HEMA:</sec_title>
						<para> Bruising, petechiae, bleeding</para>
					</section>
					<section type="none" id="sidelem4x3866">
						<sec_title>INTEG:</sec_title>
						<para> Rash, bruising</para>
					</section>
					<section type="none" id="sidelem4x3871">
						<sec_title>MISC:</sec_title>
						<para> Gingival hyperplasia</para>
					</section>
					<section type="none" id="sidelem4x3876">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3883">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted in urine (70% as metabolites)</para>
				<section type="none" id="sidelem4x3888">
					<section type="none" id="sidelem4x3889">
						<sec_title>PO:</sec_title>
						<para> Onset variable; peak 3-4 hr; duration 17-24 hr; half-life (biphasic) 4 min, 3-7 hr (terminal)</para>
					</section>
					<section type="none" id="sidelem4x3894">
						<sec_title>IV:</sec_title>
						<para> Onset 3 min, peak 3-5 min, duration 10-20 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x3899">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—prazosin, quiNIDine, fentaNYL, other antihypertensives, nitrates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of verapamil—β-blockers, cimetidine, clarithromycin, erythromycin, monitor for CV effects</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of digoxin, theophylline, cycloSPORINE, carBAMazepine, nondepolarizing muscle relaxants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of lithium</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effects—NSAIDs</para>
				<section type="none" id="sidelem4x3922">
					<section type="none" id="sidelem4x3923">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> hypotensive effects—grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x3930">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> verapamil effect—ginseng, ginkgo</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> hypertension ephedra (ma huang)</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> verapamil effect—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x3945">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, alk phos, BUN, creatinine, serum cholesterol</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3952">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3955">
					<section type="none" id="sidelem4x3956">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3964">
							<label>•</label>
							<sec_title>Cardiac status</sec_title>
							<para>
								<list id="lidelem4x3964">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cardiac status:</emphasis> B/P, pulse, respiration, ECG intervals (PR, QRS, QT); notify prescriber if pulse &lt;50 bpm, systolic B/P &lt;90 mm Hg</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3969">
								<item>
									<para>
										<emphasis alert="nurse">CHF: I&amp;O ratios, weight daily; crackles, weight gain, dyspnea, jugular venous distention</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3974">
								<item>
									<label>•</label>
									<para>Renal, hepatic studies during long-term treatment, serum potassium periodically</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3979">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3983">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anginal pain, decreased B/P, dysrhythmias</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3989">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3994">
								<item>
									<label>•</label>
									<para>To increase fluids, fiber to counteract constipation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3999">
								<item>
									<label>•</label>
									<para>How to take pulse, B/P before taking product; to keep record or graph</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4004">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on product, dizziness no longer a problem</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4009">
								<item>
									<label>•</label>
									<para>To limit caffeine consumption; to avoid alcohol products</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4014">
								<item>
									<label>•</label>
									<para>To avoid OTC or grapefruit products unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4019">
								<item>
									<label>•</label>
									<para>To comply with all areas of medical regimen: diet, exercise, stress reduction, product therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4024">
								<item>
									<label>•</label>
									<para>To change positions slowly to prevent syncope</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4029">
								<item>
									<label>•</label>
									<para>Not to discontinue abruptly; chest pain may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4035">
								<item>
									<para>
										<emphasis alert="nurse">To report chest pain, palpitations, irregular heart beats, swelling of extremities, skin irritation, rash, tremors, weakness</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4040">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned; may breastfeed (American Academy of Pediatrics)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active">
			<mono_name>vigabatrin (Rx)</mono_name>
			<info>
				<pronunciation>(vye-ga′ba-trin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x40550">Sabril</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant</class>
				<class type="chem"> GABA transaminase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4065">
				<sec_title>Action:</sec_title>
				<para>May inhibit reuptake and metabolism of GABA; may increase seizure threshold; structurally similar to GABA</para>
			</section>
			<section type="uses" id="sidelem4x4070">
				<sec_title>Uses:</sec_title>
				<para>Adjunct treatment of partial seizures in adults and children ≥12 yr, infantile spasm</para>
			</section>
			<section type="contra" id="sidelem4x4075">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product</para>
				<section type="none" id="sidelem4x4080">
					<section type="none" id="sidelem4x4081">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;2 yr, geriatric patients, renal/hepatic disease, suicidal thoughts/behaviors, abrupt discontinuation</para>
						<para>
							<bbw>Visual disturbance</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4096">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4099">
					<section type="none" id="sidelem4x4100">
						<sec_title>Partial seizures</sec_title>
						<section type="none" id="sidelem4x4108">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4108">
									<item>
										<label>•</label>
										<para> 500 mg bid, titrate in 500- mg increments at weekly intervals up to 1.5 g bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4112">
						<sec_title>Infantile spasm</sec_title>
						<section type="none" id="sidelem4x4120">
							<label>•</label>
							<sec_title>Infant &gt;1 mo, child ≤2 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4120">
									<item>
										<label>•</label>
										<para> 50 mg/kg/day in 2 divided doses, titrate in 25 to 50-mg/kg/day increments q3days, max 150 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4124">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x4132">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 50-80 ml/min, reduce dose by 25%; CCr 30-50 ml/min, reduce dose by 50%; CCr 10-30 ml/min, reduce dose by 75%</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4135">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 500 mg; powder for oral solution 500 mg</para>
					</section>
					<section type="none" id="sidelem4x4140">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4143">
							<sec_title>PO route (tab)</sec_title>
							<para>
								<list id="lidelem4x4147">
									<item>
										<label>•</label>
										<para>Give without regard to meals</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4153">
							<sec_title>PO route (oral sol)</sec_title>
							<para>
								<list id="lidelem4x4157">
									<item>
										<label>•</label>
										<para>Reconstitute immediately before using</para>
									</item>
									<item>
										<label>•</label>
										<para>Empty contents of appropriate number of packets into clean cup</para>
									</item>
									<item>
										<label>•</label>
										<para>For each packet, dissolve 10 ml water, concentration 50 mg/ml; do not use other liquids</para>
									</item>
									<item>
										<label>•</label>
										<para>Stir until dissolved, sol should be clear</para>
									</item>
									<item>
										<label>•</label>
										<para>Use calibrated oral syringe to measure correct dosage</para>
									</item>
									<item>
										<label>•</label>
										<para>Discard any unused sol</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4193">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4196">
					<section type="none" id="sidelem4x4197">
						<sec_title>CNS:</sec_title>
						<para> Headache, memory impairment, <emphasis style="italic">dizziness,</emphasis> irritability, lethargy, <emphasis style="bold">malignant hyperthermia,</emphasis> insomnia, <emphasis style="bold">suicidal ideation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4210">
						<sec_title>CV:</sec_title>
						<para> Edema</para>
					</section>
					<section type="none" id="sidelem4x4215">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="bold">Visual impairment</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4222">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, increased appetite, abdominal pain, GI bleeding, hemorrhoids, weight gain, constipation</para>
					</section>
					<section type="none" id="sidelem4x4227">
						<sec_title>GU:</sec_title>
						<para> Impotence, dysmenorrhea</para>
					</section>
					<section type="none" id="sidelem4x4232">
						<sec_title>HEMA:</sec_title>
						<para> Anemia</para>
					</section>
					<section type="none" id="sidelem4x4237">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, rash</para>
					</section>
					<section type="none" id="sidelem4x4242">
						<sec_title>RESP:</sec_title>
						<para> Coughing, <emphasis style="bold">respiratory depression, pulmonary embolism</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4249">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption &gt;95%, no protein binding, widely distributed, not metabolized, excretion in urine 80% parent drug, excretion slowed in renal disease, peak 2 hr, half-life 7.5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x4254">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—CNS depressants</para>
				<para>
					<emphasis alert="lifethreat">Increase: Serious ophthalmic effects (glaucoma, retinopathy): azaTHIOprine, chloroquine, corticosteroids, deferoxamine, ethambutol, hydroxychloroquine, interferons, loxapine, mecasermin, rh-IGF-1, pentostatin, phenothiazine, phosphodiesterase inhibitors, tamoxifen, thiothixene; avoid concurrent use</emphasis>
				</para>
				<section type="none" id="sidelem4x4264">
					<section type="none" id="sidelem4x4265">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> ALT/AST</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4272">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4275">
					<section type="none" id="sidelem4x4276">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Visual impairment:</emphasis> Prescribers must be registered with the SHARE program due to risk of permanent vision loss; if no clinical response in 2-4 wk of pediatric patients or 3 mo in adults discontinue, provide vision assessment before and after ≤ 4 wk at least q3mo, and 3-6 mo after stopping product</bbw>
						</para>
						<para>
							<list id="lidelem4x4291">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, BUN, urine creatinine q3mo in those with renal disease</para>
								</item>
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST, bilirubin</para>
								</item>
								<item>
									<label>•</label>
									<para>Description of seizures: location, duration, presence of aura</para>
								</item>
								<item>
									<label>•</label>
									<para>Mental status: mood, sensorium, affect, behavioral changes; if mental status changes, notify prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>Assistance with ambulation during early part of treatment; dizziness occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>Seizure precautions: padded side rails; move objects that may harm patient</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4322">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4326">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased seizure activity; document on patient’s chart</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4332">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4337">
								<item>
									<label>•</label>
									<para>To carry emergency ID stating patient’s name, products taken, condition, prescriber’s name and phone number</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4342">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities that require alertness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4347">
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long-term use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4352">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4360">
							<label>•</label>
							<sec_title>
								<route>To report suicidal thoughts/behaviors immediately</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x4366">
							<label>•</label>
							<sec_title>
								<route>To avoid alcohol; drowsiness, dizziness may occur</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active">
			<mono_name>vilazodone (Rx)</mono_name>
			<info>
				<pronunciation>(vil-az′oh-done)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x43740">Viibryd</tradename>
				</tradenames>
				<class type="func"> Antidepressant, miscellaneous</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4380">
				<sec_title>Action:</sec_title>
				<para>Novel antidepressant unrelated to other antidepressants, enhances serotonergic action by a dual mechanism</para>
			</section>
			<section type="uses" id="sidelem4x4385">
				<sec_title>Uses:</sec_title>
				<para>Major depression</para>
			</section>
			<section type="contra" id="sidelem4x4390">
				<sec_title>Contraindications:</sec_title>
				<para>Concomitant use of MOA inhibitors or within 14 days after discontinuing MOA inhibitor or within 14 days after discontinuing vilazodone</para>
				<section type="none" id="sidelem4x4395">
					<section type="none" id="sidelem4x4396">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), labor, infants, geriatric patients, abrupt discontinuation, bipolar disorder, bleeding, operating machinery, ECT, hepatic disease, hyponatremia, hypovolemia, substance abuse, history of seizures, serotonin syndrome, neuroleptic malignant syndrome; use with serotonin precursors (e.g., tryptophan) or serotonergic drugs; suicidal ideation, worsening depression or behavior</para>
						<para>
							<bbw>Children, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4411">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4419">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4419">
							<item>
								<label>•</label>
								<para> 10 mg × 7 days, then 20 mg × 7 days, then 40 mg/day; if taking potent CYP3A4 inhibitor, max 20 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4423">
					<section type="none" id="sidelem4x4424">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 20, 40 mg</para>
					</section>
					<section type="none" id="sidelem4x4429">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4433">
								<item>
									<label>•</label>
									<para>With food to increase absorption</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not use within 2 wk of MAOIs</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature, away from moisture, heat</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4449">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4452">
					<section type="none" id="sidelem4x4453">
						<sec_title>CNS:</sec_title>
						<para> Restlessness, dizziness, drowsiness, fatigue, mania, insomnia, migraine, <emphasis style="bold">neuroleptic-malignant–like syndrome,</emphasis> paresthesias, <emphasis style="bold">seizures, suicidal ideation,</emphasis> tremors, night sweats, dream disorders</para>
					</section>
					<section type="none" id="sidelem4x4464">
						<sec_title>CV:</sec_title>
						<para> Palpitations, ventricular extrasystole</para>
					</section>
					<section type="none" id="sidelem4x4469">
						<sec_title>EENT:</sec_title>
						<para> Cataracts, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x4474">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, flatulence, <emphasis style="italic">diarrhea, xerostomia,</emphasis> altered taste, gastroenteritis, increased appetite</para>
					</section>
					<section type="none" id="sidelem4x4485">
						<sec_title>GU:</sec_title>
						<para> Decreased libido, ejaculation disorder, increased frequency of urination, sexual dysfunction</para>
					</section>
					<section type="none" id="sidelem4x4490">
						<sec_title>HEMA:</sec_title>
						<para> Bleeding, decreased platelets</para>
					</section>
					<section type="none" id="sidelem4x4495">
						<sec_title>INTEG:</sec_title>
						<para> Sweating</para>
					</section>
					<section type="none" id="sidelem4x4500">
						<sec_title>MS:</sec_title>
						<para> Arthralgia</para>
					</section>
					<section type="none" id="sidelem4x4505">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Neonatal abstinence syndrome, withdrawal, serotonin syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x4512">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Do not use within 2 wk of MAO inhibitors</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increased: serotonin syndrome—SSRIs, SNRIs, serotonin receptor agonists, selegiline, busPIRone, dextromethorphan, ergots, fenfluramine, dexfluramine, lithium, meperidine, fentaNYL, methylphenidate, dexmethylphenidate, metoclopramide, mirtazapine, nefazodone, pentazocine, phenothiazines, haloperidol, loxapine, thiothixene, molindone, amphetamines</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increased:</emphasis> bleeding—anticoagulants, thrombolytics, platelet inhibitors, salicylates, NSAIDs</para>
				<para>
					<emphasis style="bold">Increased:</emphasis> vilazodone levels—CYP3A4 inhibitors (ketoconazole, erythromycin, efavirenz, dronedarone, clarithromycin and others)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> vilazodone effect—CYP3A4 inducers</para>
				<section type="none" id="sidelem4x4537">
					<section type="none" id="sidelem4x4538">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x4542">
								<item>
									<label>•</label>
									<para>Avoid use with grapefruit juice</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4548">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="lifethreat">Increased: serotonin syndrome—St. John’s wort</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x4554">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> sodium</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4561">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 96%-99%, metabolized by liver by CYP3A4 (major) and CYP2C19 and CYP2D (minor) and non-CYP pathways, peak 4-5 hr, half-life 25 hr</para>
			</section>
			<section type="considerations" id="sidelem4x4566">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4569">
					<section type="none" id="sidelem4x4570">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Mental status: orientation, mood behavior initially and periodically; initiate suicide precautions if indicated; history of seizures, mania</bbw>
						</para>
						<para>
							<list id="lidelem4x4584">
								<item>
									<label>•</label>
									<para>Renal/hepatic status: hyponatremia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4592">
							<label>•</label>
							<sec_title>Abrupt discontinuation<route> do not discontinue abruptly, taper, monitor for symptoms of withdrawal; if intolerable, resume previous dose and decrease more slowly</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4598">
							<label>•</label>
							<sec_title>Serotonin syndrome/neuroleptic malignant syndrome<route> nausea, vomiting, sedation, sweating, facial flushing, high B/P; discontinue product, notify prescriber</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4601">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4605">
								<item>
									<label>•</label>
									<para>Therapeutic response: remission of depressive symptoms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4611">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4616">
								<item>
									<label>•</label>
									<para>To take as directed, with food, not to double dose, that follow-up will be needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4621">
								<item>
									<label>•</label>
									<para>To avoid abrupt discontinuation unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4626">
								<item>
									<label>•</label>
									<para>Not to drive or operate machinery until effects are known</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4631">
								<item>
									<label>•</label>
									<para>Not to use other products unless approved by prescribed, do not use alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4637">
								<item>
									<para>
										<emphasis alert="nurse">To contact prescriber regarding the following: allergic reactions; personality changes (aggression, anxiety, anger, hostility); extreme sleepiness or drowsiness; feeling confused, nervous, restless, or clumsy; numbness, tingling, or burning pain in hands, arms, legs, or feet; tremors; unusual behavior or thoughts about hurting oneself</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4642">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected; to avoid breastfeeding
<bbw>Suicidal thoughts/behaviors: discuss with family the possibility of suicidal thoughts/behaviors, to notify prescriber immediately if these occur</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active" ha="yes">
			<mono_name> vinBLAStine (VLB) (Rx)</mono_name>
			<info>
				<pronunciation>(vin-blast′een)</pronunciation>
				<class type="func"> Antineoplastic</class>
				<class type="chem"> Vinca alkaloid</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4671">
				<para>
					<confusion>
						<tradename id="tnidelem4x46710">vinBLAStine</tradename>
						<drug type="generic" refid="idelem4x46710">vinCRIStine/vinorelbine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4675">
				<sec_title>Action:</sec_title>
				<para>Inhibits mitotic activity, arrests cell cycle at metaphase; inhibits RNA synthesis, blocks cellular use of glutamic acid needed for purine synthesis; vesicant</para>
			</section>
			<section type="uses" id="sidelem4x4680">
				<sec_title>Uses:</sec_title>
				<para>Breast, testicular cancer, lymphomas, neuroblastoma; Hodgkin’s/non-Hodgkin’s lymphoma; mycosis fungoides, histiocytosis, Kaposi’s sarcoma, Langerhans cell histiocytosis</para>
				<section type="none" id="sidelem4x4685">
					<section type="none" id="sidelem4x4686">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Lung, bladder, prostate cancer; desmoid tumor, malignant melanoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4691">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, infants, hypersensitivity, leukopenia, granulocytopenia, bone marrow suppression, infection</para>
				<para>
					<bbw>Intrathecal use</bbw>
				</para>
				<section type="none" id="sidelem4x4706">
					<section type="none" id="sidelem4x4707">
						<sec_title>Precautions:</sec_title>
						<para> Renal/hepatic disease, tumor lysis syndrome</para>
						<para>
							<bbw>Extravasation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4722">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4725">
					<section type="none" id="sidelem4x4726">
						<sec_title>Breast cancer</sec_title>
						<section type="none" id="sidelem4x4734">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4734">
									<item>
										<label>•</label>
										<para> 4.5 mg/m<emphasis style="sup">2</emphasis> on day 1 of every 21 days in combination with DOXOrubicin and thiotepa</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4741">
						<sec_title>Hodgkin’s disease</sec_title>
						<section type="none" id="sidelem4x4749">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4749">
									<item>
										<label>•</label>
										<para> 6 mg/m<emphasis style="sup">2</emphasis> on days 1 and 15 of every 28 days with DOXOrubicin, bleomycin, dacarbazine (ABVD regimen)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4759">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4759">
									<item>
										<label>•</label>
										<para> 2.5-6 mg/m<emphasis style="sup">2</emphasis>/day once q1-2wk × 3-6 wk, max weekly dose 12.5 mg/m<emphasis style="sup">2</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4768">
						<sec_title>Available forms:</sec_title>
						<para> Inj, powder 10 mg for 10 ml IV; sol for inj 1 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x4773">
						<sec_title>Administer:</sec_title>
						<para>
							<bbw>Hyaluronidase 150 units/ml in 1 ml NaCl, warm compress for extravasation for vesicant activity treatment</bbw>
						</para>
						<para>
							<bbw>Do not administer intrathecally; fatal</bbw>
						</para>
						<section type="none" id="sidelem4x4796">
							<sec_title>IV inj route</sec_title>
							<para>
								<list id="lidelem4x4800">
									<item>
										<label>•</label>
										<para>After diluting 10 mg/10 ml NaCl; give through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock or directly over 1 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4809">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x4813">
									<item>
										<label>•</label>
										<para>Further dilute in 50-100 ml of NS, infuse over 15-30 min</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Additive compatibilities:</emphasis> Bleomycin</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Bleomycin, CISplatin, cyclophosphamide, droperidol, fluorouracil, leucovorin, methotrexate, metoclopramide, mitoMYcin, vinCRIStine</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Allopurinol, amifostine, amphotericin B cholesteryl, aztreonam, bleomycin, CISplatin, cyclophosphamide, DOXOrubicin, DOXOrubicin liposome, droperidol, filgrastim, fludarabine, fluorouracil, granisetron, heparin, leucovorin, melphalan, methotrexate, metoclopramide, mitoMYcin, ondansetron, PACLitaxel, piperacillin/tazobactam, sargramostim, teniposide, thiotepa, vinCRIStine, vinorelbine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4831">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4834">
					<section type="none" id="sidelem4x4835">
						<sec_title>CNS:</sec_title>
						<para> Paresthesias, peripheral neuropathy, depression, headache, <emphasis style="bold">seizures,</emphasis> malaise</para>
					</section>
					<section type="none" id="sidelem4x4843">
						<sec_title>CV:</sec_title>
						<para> Tachycardia, orthostatic hypo/hypertension</para>
					</section>
					<section type="none" id="sidelem4x4848">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> ileus, <emphasis style="italic">anorexia, stomatitis, constipation,</emphasis> abdominal pain, <emphasis style="bold">GI/rectal bleeding, hepatotoxicity,</emphasis> pharyngitis</para>
					</section>
					<section type="none" id="sidelem4x4862">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, <emphasis style="bold">renal failure,</emphasis> hyperuricemia</para>
					</section>
					<section type="none" id="sidelem4x4870">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, myelosuppression, agranulocytosis, granulocytosis, aplastic anemia, neutropenia, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4877">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, alopecia,</emphasis> photosensitivity, <emphasis style="bold">extravasation, tissue necrosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4887">
						<sec_title>META:</sec_title>
						<para> SIADH</para>
					</section>
					<section type="none" id="sidelem4x4892">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Fibrosis, pulmonary infiltrate, bronchospasm</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4899">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Tumor lysis syndrome (TLS)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4906">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life (triphasic) &lt;5 min, 50-155 min, 23-85 hr; metabolized in liver; excreted in urine, feces; crosses blood-brain barrier</para>
			</section>
			<section type="interactions" id="sidelem4x4911">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> synergism: bleomycin</para>
				<section type="none" id="sidelem4x4926">
					<label>•</label>
					<sec_title>
						<route>Do not use with radiation</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, anticoagulants, thrombolytics, antiplatelets</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity, bone marrow suppression—antineoplastics</para>
				<para>
					<emphasis alert="lifethreat">Increase: action of methotrexate</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions—live virus vaccines</para>
				<para>
					<emphasis alert="nurse">Increase: toxicity—CYP3A4 inhibitors (aprepitant, antiretroviral protease inhibitors, clarithromycin, danazol, delavirdine, diltiazem, erythromycin, fluconazole, FLUoxetine, fluvoxaMINE, imatinib, ketoconazole, mibefradil, nefazodone, telithromycin, voriconazole)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> vinBLAStine effect—CYP3A4 inducers (barbiturates, bosentan, carBAMazepine, efavirenz, phenytoins, nevirapine, rifabutin, rifampin)</para>
				<section type="none" id="sidelem4x4953">
					<section type="none" id="sidelem4x4954">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x4958">
								<item>
									<label>•</label>
									<para>Avoid use with St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4964">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid, bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, platelets, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4975">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4978">
					<section type="none" id="sidelem4x4979">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4985">
								<item>
									<para>
										<emphasis alert="nurse">CBC, differential, platelet count weekly; withhold product if WBC is &lt;2000/mm<emphasis style="sup">3</emphasis> or platelet count is &lt;75,000/mm<emphasis style="sup">3</emphasis>; notify prescriber; RBC, Hct, Hgb may be decreased, nadir occurs on days 4-10 and continues for another 1-2 wk</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4999">
							<label>•</label>
							<sec_title>Tumor lysis syndrome<route> monitor for hyperkalemia, hyperphosphatemia, hyperuricemia; usually occurs with leukemia, lymphoma; alkalinization of the urine, allopurinol should be used to prevent urate nephrophy; monitor electrolytes and renal function (BUN, uric acid, urine CCR)</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5005">
							<label>•</label>
							<sec_title>Hepatitis<route> transient hepatitis may occur with continuous IV</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5008">
								<item>
									<label>•</label>
									<para>Bleeding: hematuria, guaiac, bruising, petechiae, mucosa or orifices</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5016">
							<label>•</label>
							<sec_title>Bronchospasm<route> can be life-threatening; usually occurs when giving mitoMYcin</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5019">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5024">
								<item>
									<label>•</label>
									<para>Sensitivity of feet/hands, which precedes neuropathy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5029">
								<item>
									<label>•</label>
									<para>Jaundiced skin, sclera; dark urine, clay-colored stools, itchy skin, abdominal pain, fever, diarrhea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5034">
								<item>
									<label>•</label>
									<para>Buccal cavity q8hr for dryness, sores, ulcerations, white patches, oral pain, bleeding, dysphagia
<bbw>Local irritation, pain, burning, discoloration at inj site, extravasation</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5051">
							<label>•</label>
							<sec_title>Symptoms indicating severe allergic reaction<route> rash, pruritus, urticaria, purpuric skin lesions, itching, flushing</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5054">
								<item>
									<label>•</label>
									<para>Increased fluid intake to 2-3 L/day to prevent urate deposits, calculi formation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5059">
								<item>
									<label>•</label>
									<para>Brushing of teeth bid-tid with soft brush or cotton-tipped applicator for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5064">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5068">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5074">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5079">
								<item>
									<label>•</label>
									<para>To report any changes in breathing or coughing; to avoid exposure to persons with infection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5084">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that a wig or hairpiece may make patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5089">
								<item>
									<label>•</label>
									<para>To report change in gait or numbness in extremities; may indicate neuropathy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5094">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5099">
								<item>
									<label>•</label>
									<para>To report any bleeding, white spots, ulcerations in mouth to prescriber; to examine mouth daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5104">
								<item>
									<label>•</label>
									<para>To wear sunscreen, protective clothing, sunglasses</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5109">
								<item>
									<label>•</label>
									<para>To avoid receiving vaccinations</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5115">
								<item>
									<para>
										<emphasis alert="nurse">Pregnancy: pregnancy (D); to avoid breastfeeding; that product may cause male infertility</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5123">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected; to avoid persons with known infections</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x5129">
							<label>•</label>
							<sec_title>Infection<route> to report sore throat, flulike symptoms</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active" ha="yes">
			<mono_name> vinCRIStine (VCR) (Rx)</mono_name>
			<info>
				<pronunciation>(vin-kris′teen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x51390">Vincasar PFS</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="19" status="active">
			<mono_name>VinCRIStine Liposomal (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x51440">Marqibo</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Vinca alkaloid</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5154">
				<para>
					<confusion>
						<tradename id="tnidelem4x51540">vinCRIStine</tradename>
						<drug type="generic" refid="idelem4x51540">vinBLAStine/vinorelbine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5158">
				<sec_title>Action:</sec_title>
				<para>Inhibits mitotic activity, arrests cell cycle at metaphase; inhibits RNA synthesis, blocks cellular use of glutamic acid needed for purine synthesis; vesicant</para>
			</section>
			<section type="uses" id="sidelem4x5163">
				<sec_title>Uses:</sec_title>
				<para>Lymphomas, neuroblastoma, Hodgkin’s disease, acute lymphoblastic and other leukemias, rhabdomyosarcoma, Wilms’ tumor, non-Hodgkin’s lymphoma, malignant glioma, soft-tissue sarcoma; liposomal: Philadelphia chromosome-negative ALL in second or greater relapse or that has progressed after ≥2 antileukemia therapies</para>
				<section type="none" id="sidelem4x5168">
					<section type="none" id="sidelem4x5169">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Lung, breast, colorectal, head/neck, osteogenic sarcomas; small-cell lung cancer, trophoblastic disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5174">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, infants, hypersensitivity, radiation therapy</para>
				<para>
					<bbw>Intrathecal use</bbw>
				</para>
				<section type="none" id="sidelem4x5189">
					<section type="none" id="sidelem4x5190">
						<sec_title>Precautions:</sec_title>
						<para> Renal/hepatic disease, hypertension, neuromuscular disease</para>
						<para>
							<bbw>Extravasation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5205">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5213">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x5213">
							<item>
								<label>•</label>
								<para> 0.4-1.4 mg/m<emphasis style="sup">2</emphasis>/wk, max 2 mg</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5223">
					<label>•</label>
					<sec_title>Child<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x5223">
							<item>
								<label>•</label>
								<para> 1-2 mg/m<emphasis style="sup">2</emphasis>/wk, max 2 mg</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5230">
					<section type="none" id="sidelem4x5231">
						<section type="none" id="sidelem4x5232">
							<sec_title>Liposomal</sec_title>
							<section type="none" id="sidelem4x5240">
								<label>•</label>
								<sec_title>Adult<route> IV</route></sec_title>
								<para>
									<list id="lidelem4x5240">
										<item>
											<label>•</label>
											<para> 2.25 mg/m<emphasis style="sup">2</emphasis> over 1 hr q7days</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x5247">
					<section type="none" id="sidelem4x5248">
						<sec_title>Available forms:</sec_title>
						<para> Inj 1 mg/ml; liposomal 5 mg/31 ml injection kit</para>
						<para>
							<bbw>Do not give intrathecally; fatal</bbw>
						</para>
						<section type="none" id="sidelem4x5263">
							<sec_title>VinCRIStine</sec_title>
							<para/>
						</section>
						<section type="none" id="sidelem4x5267">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x5271">
									<item>
										<label>•</label>
										<para>After diluting with diluent provided or 1 mg/10 ml sterile water or NaCl; give through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock or directly over 1 min; do not use 5-mg vial for single doses
<bbw>Hyaluronidase 150 units/ml in 1 ml NaCl; apply warm compress for extravasation</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5289">
							<sec_title>IV route</sec_title>
							<para/>
						</section>
						<section type="none" id="sidelem4x5293">
							<sec_title>VinCRIStine Liposomal</sec_title>
							<para>
								<list id="lidelem4x5297">
									<item>
										<label>•</label>
										<para>Supplied in single-use kit, inspect for particulates after preparation in pharmacy, give using separate line over 1 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">VinCRIStine Y-site compatibilities </emphasis>Acyclovir, alemtuzumab, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B cholesteryl, amphotericin B lipid complex, amphotericin B liposome, ampicillin, ampicillin–sulbactam, anidulafungin, argatroban, arsenic trioxide, asparaginase, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, capreomycin, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefoperazone, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, clindamycin, codeine, cyclophosphamide, cycloSPORINE, cytarabine, D5W-dextrose 5%, dacarbazine, DACTINomycin, DAPTOmycin, DAUNOrubicin, DAUNOrubicin citrate liposome, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doxacurium, doxapram, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, gallium, ganciclovir, garenoxacin, gatifloxacin, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hydrocortisone sodium phosphate/succinate, HYDROmorphone, hydrOXYzine, ifosfamide, imipenem-cilastatin, inamrinone, insulin, regular, isoproterenol, ketorolac, labetalol, lepirudin, leucovorin, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, methadone, methohexital, methotrexate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoMYcin, mitoXANtrone, mivacurium, morphine, moxifloxacin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, PACLitaxel (solvent/surfactant), palonosetron, pamidronate, pancuronium, PEMEtrexed, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin–tazobactam, potassium acetate/chloride/phosphates, procainamide, prochlorperazine, promethazine, propranolol, quinupristin-dalfopristin, ranitidine, remifentanil, riTUXimab, rocuronium, sargramostim, sodium acetate/phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin–clavulanate, tigecycline, tirofiban, tobramycin, topotecan, trastuzumab, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5307">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5310">
					<section type="none" id="sidelem4x5311">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Decreased reflexes, numbness, weakness, motor difficulties,</emphasis> CNS depression, cranial nerve paralysis, <emphasis style="bold">seizures,</emphasis> peripheral neuropathy</para>
					</section>
					<section type="none" id="sidelem4x5322">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension</para>
					</section>
					<section type="none" id="sidelem4x5327">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Diplopia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5334">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, stomatitis, constipation,</emphasis><emphasis style="bold">paralytic ileus,</emphasis><emphasis style="italic">abdominal pain,</emphasis><emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5347">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal tubular obstruction</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5354">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, myelosuppression, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5361">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Alopecia,</emphasis> extravasation</para>
					</section>
					<section type="none" id="sidelem4x5369">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Tumor lysis syndrome (TLS)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5376">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life (triphasic) &lt;5 min, 50-155 min, 23-85 hr; metabolized in liver; excreted in bile, feces; crosses placental, blood-brain barrier</para>
			</section>
			<section type="interactions" id="sidelem4x5381">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> immune response—vaccines, toxoids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> digoxin level—digoxin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> vinCRIStine effect—CYP3A4 inducers (barbiturates, bosentan, carBAMazepine, efavirenz, phenytoins, nevirapine, rifabutin, rifampin)</para>
				<section type="none" id="sidelem4x5404">
					<label>•</label>
					<sec_title>
						<route>Do not use with radiation</route>
					</sec_title>
				</section>
				<section type="none" id="sidelem4x5410">
					<label>•</label>
					<sec_title>Acute pulmonary reactions<route> mitoMYcin c</route></sec_title>
				</section>
				<para>
					<list id="lidelem4x5414">
						<item>
							<para>
								<emphasis alert="nurse">Increase: toxicity—CYP3A4 inhibitors (aprepitant, antiretroviral protease inhibitors, clarithromycin, danazol, delavirdine, diltiazem, erythromycin, fluconazole, FLUoxetine, fluvoxaMINE, imatinib, ketoconazole, mibefradil, nefazodone, telithromycin, voriconazole)</emphasis>
							</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x5419">
					<section type="none" id="sidelem4x5420">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x5424">
								<item>
									<label>•</label>
									<para>Avoid use with St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5430">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, WBC, platelets, sodium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5441">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5444">
					<section type="none" id="sidelem4x5445">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5450">
								<item>
									<label>•</label>
									<para>CBC, differential, platelet count before each dose; withhold product if WBC is &lt;4000/mm<emphasis style="sup">3</emphasis> or platelet count is &lt;75,000/mm<emphasis style="sup">3</emphasis>; notify prescriber; RBC, Hct, Hgb; may be decreased</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5464">
							<label>•</label>
							<sec_title>Bronchospasm<route> more common with mitoMYcin</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5467">
								<item>
									<label>•</label>
									<para>Hepatic studies before, during therapy (bilirubin, AST, ALT, LDH) as needed or monthly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5472">
								<item>
									<label>•</label>
									<para>Sensitivity of feet/hands, which precedes neuropathy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5480">
							<label>•</label>
							<sec_title>Tumor lysis syndrome<route> hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia; more common in leukemia, lymphoma; use alkalinization of urine with allopurinol, monitor electrolytes, renal function (BUN, urine, CCR, uric acid)</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5494">
							<sec_title>Intrathecal administration</sec_title>
							<section type="none" id="sidelem4x5502">
								<label>•</label>
								<sec_title>Bleeding</sec_title>
								<para>
									<list id="lidelem4x5502">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Bleeding:</emphasis> hematuria, guaiac, bruising, petechiae, mucosa or orifices q8hr</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x5506">
									<item>
										<label>•</label>
										<para>Effects of alopecia on body image; discuss feelings about body changes</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x5511">
									<item>
										<label>•</label>
										<para>Buccal cavity q8hr for dryness, sores, ulcerations, white patches, oral pain, bleeding, dysphagia</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x5516">
									<item>
										<label>•</label>
										<para>Symptoms indicating severe allergic reaction: rash, pruritus, urticaria, purpuric skin lesions, itching, flushing</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x5521">
									<item>
										<label>•</label>
										<para>Brushing of teeth bid-tid with soft brush or cotton-tipped applicator for stomatitis; use unwaxed dental floss</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5526">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5530">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5536">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5541">
								<item>
									<label>•</label>
									<para>To report change in gait or numbness in extremities; may indicate neuropathy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5546">
								<item>
									<label>•</label>
									<para>To report any bleeding, white spots, or ulcerations in mouth to prescriber; to examine mouth daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5551">
								<item>
									<label>•</label>
									<para>To increase bulk, fluids, exercise to prevent constipation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5559">
							<label>•</label>
							<sec_title>Infection<route> to report sore throat, fever, flulike symptoms; avoid persons with known infection</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5562">
								<item>
									<label>•</label>
									<para>To avoid vaccinations</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5567">
								<item>
									<label>•</label>
									<para>That hair may be lost; that hair will grow back but with different texture, color</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5575">
							<label>•</label>
							<sec_title>Pregnancy (D)<route> to notify prescriber if pregnancy is planned or suspected</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5579">
								<item>
									<para>
										<emphasis alert="nurse">To use effective contraception during and for 2 mo after therapy, pregnancy (D), to avoid breastfeeding</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active" ha="yes">
			<mono_name> vinorelbine (Rx)</mono_name>
			<info>
				<pronunciation>(vi-nor′el-bine)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x55910">Navelbine</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Semisynthetic vinca alkaloid</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x5601">
				<sec_title>Action:</sec_title>
				<para>Inhibits mitotic spindle activity, arrests cell cycle at metaphase; inhibits RNA synthesis, blocks cellular use of glutamic acid needed for purine synthesis; vesicant</para>
			</section>
			<section type="uses" id="sidelem4x5606">
				<sec_title>Uses:</sec_title>
				<para>Unresectable advanced non–small-cell lung cancer (NSCLC) stage IV; may be used alone or in combination with CISplatin for stage III or IV NSCLC</para>
				<section type="none" id="sidelem4x5611">
					<section type="none" id="sidelem4x5612">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hodgkin’s disease, breast/ovarian/head/neck cancer, desmoid tumor</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5617">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, infants, hypersensitivity, granulocyte count &lt;1000 cells/mm<emphasis style="sup">3</emphasis> pretreatment</para>
				<para>
					<bbw>Severe neutropenia, intrathecal administration</bbw>
				</para>
				<section type="none" id="sidelem4x5635">
					<section type="none" id="sidelem4x5636">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, renal/hepatic/pulmonary/neurologic disease, anemia, bone marrow suppression</para>
						<para>
							<bbw>Extravasation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5651">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5659">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x5659">
							<item>
								<label>•</label>
								<para> 30 mg/m<emphasis style="sup">2</emphasis>/wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5669">
					<label>•</label>
					<sec_title>ANC 1000-1499<route> Give 50% of dose; &lt;1000, hold dose; &lt;1000 × 3 wk, discontinue</route></sec_title>
				</section>
				<section type="none" id="sidelem4x5672">
					<section type="none" id="sidelem4x5673">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x5681">
							<label>•</label>
							<sec_title>Adult<route> IV total bilirubin 2.1-3 mg/dl 15 mg/m</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5692">
						<sec_title>Available forms:</sec_title>
						<para> Inj 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x5697">
						<sec_title>Administer:</sec_title>
						<para>
							<bbw>Do not give intrathecally; fatal</bbw>
						</para>
						<section type="none" id="sidelem4x5710">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x5714">
									<item>
										<label>•</label>
										<para>Dilute to 0.5-2 mg/ml with 0.9% NaCl, 0.45% NaCl, D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">5</emphasis>/0.45% NaCl, LR, Ringer’s sol, give over 6-10 min into <emphasis style="sans-serif">Y</emphasis>-site or central line, flush line
<bbw>Hyaluronidase 150 units/ml in 1 ml NaCl, warm compress for extravasation for vesicant activity treatment</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5738">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x5742">
									<item>
										<label>•</label>
										<para>40 mg/m<emphasis style="sup">2</emphasis> q3wk after IV bol of 8 mg/m<emphasis style="sup">2</emphasis>; may be given in combination with DOXOrubicin, fluorouracil, CISplatin</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amikacin, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, CARBOplatin, carmustine, cefotaxime, cefTAZidime, ceftizoxime, chlorproMAZINE, cimetidine, CISplatin, clindamycin, cyclophosphamide, cytarabine, dacarbazine, DACTINomycin, DAUNOrubicin, dexamethasone, diphenhydrAMINE, DOXOrubicin, DOXOrubicin liposome, doxycycline, droperidol, enalaprilat, etoposide, famotidine, filgrastim, floxuridine, fluconazole, fludarabine, gallium, gentamicin, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, LORazepam, mannitol, mechlorethamine, melphalan, meperidine, mesna, methotrexate, metoclopramide, metroNIDAZOLE, minocycline, mitoXANtrone, morphine, nalbuphine, netilmicin, ondansetron, plicamycin, streptozocin, teniposide, ticarcillin, ticarcillin-clavulanate, tobramycin, vancomycin, vinBLAStine, vinCRIStine, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5758">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5761">
					<section type="none" id="sidelem4x5762">
						<sec_title>CNS:</sec_title>
						<para> Paresthesias, peripheral neuropathy, depression, headache, <emphasis style="bold">seizures,</emphasis> weakness, jaw pain, asthenia</para>
					</section>
					<section type="none" id="sidelem4x5770">
						<sec_title>CV:</sec_title>
						<para> Chest pain</para>
					</section>
					<section type="none" id="sidelem4x5775">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> ileus, <emphasis style="italic">anorexia, stomatitis,</emphasis> constipation, abdominal pain, <emphasis style="italic">diarrhea,</emphasis><emphasis style="bold">hepatotoxicity, GI obstruction/perforation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5790">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, anemia, thrombocytopenia, granulocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5797">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, alopecia,</emphasis> photosensitivity, inj site reaction, necrosis</para>
					</section>
					<section type="none" id="sidelem4x5805">
						<sec_title>META:</sec_title>
						<para> SIADH</para>
					</section>
					<section type="none" id="sidelem4x5810">
						<sec_title>MS:</sec_title>
						<para> Myalgia</para>
					</section>
					<section type="none" id="sidelem4x5815">
						<sec_title>RESP:</sec_title>
						<para> SOB, <emphasis style="bold">dyspnea, pulmonary edema, acute bronchospasm, acute respiratory distress syndrome (ARDS)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5822">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 27-43 hr; peak 1-2 hr; highly bound to platelets, lymphocytes; metabolized in liver; excreted in feces; small amount unchanged in kidneys</para>
			</section>
			<section type="interactions" id="sidelem4x5827">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, anticoagulants</para>
				<para>
					<emphasis alert="nurse">Increase: toxicity—CYP3A4 inhibitors (aprepitant, antiretroviral protease inhibitors, clarithromycin, danazol, delavirdine, diltiazem, erythromycin, fluconazole, FLUoxetine, fluvoxaMINE, imatinib, ketoconazole, mibefradil, nefazodone, telithromycin, voriconazole)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> vinorelbine effect—CYP3A4 inducers (barbiturates, bosentan, carBAMazepine, efavirenz, phenytoins, nevirapine, rifabutin, rifampin)</para>
				<section type="none" id="sidelem4x5843">
					<section type="none" id="sidelem4x5844">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x5848">
								<item>
									<label>•</label>
									<para>Avoid use with St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5854">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, WBC, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5865">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5868">
					<section type="none" id="sidelem4x5869">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5874">
								<item>
									<label>•</label>
									<para>B/P (baseline, q15min) during administration
<bbw>CBC, differential, platelet count before each dose; withhold product if WBC is &lt;4000/mm3 or platelet count is &lt;75,000/mm3; notify prescriber of results; recovery will take 3 wk</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5897">
							<label>•</label>
							<sec_title>Bronchospasm<route> more common with mitoMYcin; also dyspnea, wheezing; may be treated with oxygen, bronchodilators, corticosteroids, especially if there is underlying pulmonary disease</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5900">
								<item>
									<label>•</label>
									<para>Respiratory status: dyspnea, crackles, unproductive cough, chest pain, tachypnea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5905">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr before, during therapy; I&amp;O ratio; report fall in urine output to &lt;30 ml/hr; decreased hyperuricemia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5913">
							<label>•</label>
							<sec_title>
								<route>Infection,</route>
							</sec_title>
							<para>
								<list id="lidelem4x5913">
									<item>
										<label>•</label>
										<para> cold, fever, sore throat; notify prescriber if these occur; effects of alopecia on body image</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5920">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x5920">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> hematuria, guaiac, bruising, petechiae, mucosa or orifices, no rectal temperatures; avoid IM inj; apply pressure to venipuncture sites</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5924">
								<item>
									<label>•</label>
									<para>Hepatic function tests: AST, ALT, bilirubin, LDH</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5930">
								<item>
									<para>
										<emphasis alert="nurse">Severe allergic reactions: rash, pruritus, urticaria, itching, flushing, bronchospasm, hypotension; EPINEPHrine and crash cart should be nearby</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5938">
							<label>•</label>
							<sec_title>Neurologic status<route> numbness, pain, tingling, loss of Achilles reflex, weakness, palsies</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5941">
								<item>
									<label>•</label>
									<para>Brushing of teeth bid-tid with soft brush or cotton-tipped applicator for stomatitis; unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5946">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5950">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5956">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x5964">
							<label>•</label>
							<sec_title>
								<route>To report change in gait or numbness in extremities, continuing constipation; may indicate neurotoxicity</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x5967">
								<item>
									<label>•</label>
									<para>To examine mouth daily for bleeding, white spots, ulcerations; to notify prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5975">
							<label>•</label>
							<sec_title>Infection<route> report sore throat, fever, flulike symptoms</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5978">
								<item>
									<label>•</label>
									<para>To avoid crowds, people with infections, vaccinations, OTC products</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5984">
								<item>
									<para>
										<emphasis alert="nurse">Pregnancy: notify prescriber if pregnancy is planned or suspected; to use effective contraception during treatment and for ≥2 mo after product is discontinued, pregnancy (D); to avoid breastfeeding</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5989">
								<item>
									<label>•</label>
									<para>That hair may be lost; that hair will grow back but with different texture, color</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="21" status="active" ha="yes">
			<mono_name> vismodegib</mono_name>
			<info>
				<pronunciation>(vis′moe-deg′ib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x60010">Erivedge</tradename>
				</tradenames>
				<class type="func"> Antineoplastic biologic response modifier</class>
				<class type="chem"> Signal transduction inhibitor (STI)</class>
			</info>
			<section type="actions" id="sidelem4x6011">
				<sec_title>Action:</sec_title>
				<para>A hedgehog (Hh) signaling pathway inhibitor</para>
			</section>
			<section type="uses" id="sidelem4x6016">
				<sec_title>Uses:</sec_title>
				<para>Patients who have metastatic basal cell carcinoma, locally advanced, that has recurred after surgery and who are not candidates for surgery/radiation</para>
			</section>
			<section type="contra" id="sidelem4x6021">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, breastfeeding</para>
				<para>
					<bbw>Intrauterine fetal death, male-mediated teratogenicity, pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x6036">
					<section type="none" id="sidelem4x6037">
						<sec_title>Precautions:</sec_title>
						<para> Children, blood donation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6042">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6050">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6050">
							<item>
								<label>•</label>
								<para> 150 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6054">
					<section type="none" id="sidelem4x6055">
						<sec_title>Available forms:</sec_title>
						<para> Cap 150 mg</para>
					</section>
					<section type="none" id="sidelem4x6060">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6064">
								<item>
									<label>•</label>
									<para>Give without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Swallow whole, do not open or crush caps</para>
								</item>
								<item>
									<label>•</label>
									<para>If a dose is missed, do not take additional dose, take at usual time</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at 77°F (25°C)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6085">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6088">
					<section type="none" id="sidelem4x6089">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, dysgeusia</para>
					</section>
					<section type="none" id="sidelem4x6094">
						<sec_title>GU:</sec_title>
						<para> Amenorrhea, azotemia</para>
					</section>
					<section type="none" id="sidelem4x6099">
						<sec_title>INTEG:</sec_title>
						<para> Alopecia</para>
					</section>
					<section type="none" id="sidelem4x6104">
						<sec_title>META:</sec_title>
						<para> Hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x6109">
						<sec_title>MISC:</sec_title>
						<para> Fatigue, decreased weight</para>
					</section>
					<section type="none" id="sidelem4x6114">
						<sec_title>MS:</sec_title>
						<para> Arthralgia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6119">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding &gt;99%, elimination half-life 4 days</para>
			</section>
			<section type="interactions" id="sidelem4x6124">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of each product—Pgp inhibitors (amiodarone, clarithromycin, cycloSPORINE, diltiazem, erythromycin, indinavir, itraconazole, ketoconazole, nelfinavir, niCARdipine, propafenone, quiNIDine, ritonavir, saquinavir, tacrolimus, tamoxifen, verapamil); CYP2C19 substrates (amitriptyline, clomiPRAMINE, imipramine, citalopram, diazepam, phenytoin, PHENobarbital, lansoprazole, omeprazole, pantoprazole, RABEprazole, esomeprazole, clopidogrel, proguanil, propranolol, carisoprodol, chloramphenicol, cyclophosphamide, indomethacin, nelfinavir, nilutamide, progesterone, teniposide, warfarin)</para>
			</section>
			<section type="considerations" id="sidelem4x6131">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6134">
					<section type="none" id="sidelem4x6135">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Pregnancy (D): verify pregnancy status of all women within 7 days before starting therapy; effective contraception is needed during and for 7 mo after treatment; men receiving this product should use condoms with spermicide (even after vasectomy) during sexual intercourse with female partners and for 2 mo after the last dose; report exposure during pregnancy to the Genentech Adverse Event Line</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x6148">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6152">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased spread of tumor</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6158">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>Pregnancy (D): teach patient to notify their provider immediately if pregnancy is suspected (or in a female partner for male patients); effective contraception is needed during and for 7 mo after treatment; men receiving this product should use condoms with spermicide (even after vasectomy) during sexual intercourse with female partners and for 2 mo after the last dose; if product is used during pregnancy or if the patient becomes pregnant during use, the woman (or female partner for male patients) should be apprised of the potential hazard to the fetus; encourage exposed women (either directly or through seminal fluid) to participate in the ERIVEDGE pregnancy pharmacovigilance program</bbw>
						</para>
						<para>
							<list id="lidelem4x6171">
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results</para>
								</item>
								<item>
									<label>•</label>
									<para>If dose is missed, do not take, but resume scheduled doses, swallow whole</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not donate blood during therapy or for ≥7 months after conclusion of product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active">
			<mono_name>vitamin A (Rx, <emphasis style="smallcaps">po-otc,</emphasis> Rx-IM)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x61931">Aquasol A</tradename>
					<tradename id="tnidelem4x61930">Vitamin A</tradename>
				</tradenames>
				<class type="func"> Vitamin, fat soluble</class>
				<class type="chem"> Retinol</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg> <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x6203">
				<sec_title>Action:</sec_title>
				<para>Needed for normal bone, tooth development; visual dark adaptation; skin disease; mucosa tissue repair; assists with production of adrenal steroids, cholesterol, RNA</para>
			</section>
			<section type="uses" id="sidelem4x6208">
				<sec_title>Uses:</sec_title>
				<para>Vit A deficiency</para>
			</section>
			<section type="contra" id="sidelem4x6213">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>) (IM), hypersensitivity to vit A, malabsorption syndrome, hypervitaminosis A, IV administration</para>
				<section type="none" id="sidelem4x6218">
					<section type="none" id="sidelem4x6219">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) (PO), breastfeeding, impaired renal function, children, hepatic disease, infants, alcoholism, hepatitis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6224">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6232">
					<label>•</label>
					<sec_title>Adult and child &gt;8 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6232">
							<item>
								<label>•</label>
								<para> 100,000-500,000 international units/day × 3 days then 50,000 international units/day × 2 wk; dose based on severity of deficiency; maintenance 10,000-20,000 international units for 2 mo</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6239">
					<label>•</label>
					<sec_title>Child 1-8 yr<route> IM</route></sec_title>
					<para>
						<list id="lidelem4x6239">
							<item>
								<label>•</label>
								<para> 5000-15,000 international units/day × 10 days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6246">
					<label>•</label>
					<sec_title>Infant &lt;1 yr<route> IM</route></sec_title>
					<para>
						<list id="lidelem4x6246">
							<item>
								<label>•</label>
								<para> 5000-15,000 international units × 10 days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6250">
					<section type="none" id="sidelem4x6251">
						<sec_title>Maintenance</sec_title>
						<section type="none" id="sidelem4x6259">
							<label>•</label>
							<sec_title>Child 4-8 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x6259">
									<item>
										<label>•</label>
										<para> 15,000 international units/day × 2 mo</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6266">
							<label>•</label>
							<sec_title>Child &lt;4 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x6266">
									<item>
										<label>•</label>
										<para> 10,000 international units/day × 2 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6270">
						<sec_title>Available forms:</sec_title>
						<para> Caps 10,000, 25,000, 50,000 international units; drops 5000 international units; inj 50,000 international units/ml; tabs 10,000, 25,000, 50,000 international units</para>
					</section>
					<section type="none" id="sidelem4x6275">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6278">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x6282">
									<item>
										<label>•</label>
										<para>With food (PO) for better absorption</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not administer IV because of risk of anaphylactic shock; IM only</para>
									</item>
									<item>
										<label>•</label>
										<para>Oral preparations not indicated for vit A deficiency in those with malabsorption syndrome</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight, light-resistant container</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6303">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x6307">
									<item>
										<label>•</label>
										<para>Give deep in large muscle mass; do not use deltoid muscle for administration of &gt;1 ml</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6313">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6316">
					<section type="none" id="sidelem4x6317">
						<sec_title>CNS:</sec_title>
						<para> Headache, <emphasis style="bold">increased intracranial pressure, intracranial hypertension,</emphasis> lethargy, malaise</para>
					</section>
					<section type="none" id="sidelem4x6325">
						<sec_title>EENT:</sec_title>
						<para> Gingivitis, papilledema, exophthalmos, inflammation of tongue and lips</para>
					</section>
					<section type="none" id="sidelem4x6330">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, abdominal pain, <emphasis style="bold">jaundice</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6337">
						<sec_title>INTEG:</sec_title>
						<para> Drying of skin, pruritus, increased pigmentation, night sweats, alopecia</para>
					</section>
					<section type="none" id="sidelem4x6342">
						<sec_title>META:</sec_title>
						<para> Hypomenorrhea, hypercalcemia</para>
					</section>
					<section type="none" id="sidelem4x6347">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, retarded growth, hard areas on bone</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6352">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Stored in liver, kidneys, fat; excreted (metabolites) in urine, feces</para>
			</section>
			<section type="interactions" id="sidelem4x6357">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of vit A—corticosteroids, oral contraceptives</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of vit A—mineral oil, cholestyramine, colestipol</para>
				<section type="none" id="sidelem4x6368">
					<section type="none" id="sidelem4x6369">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False increase:</emphasis> bilirubin, serum cholesterol</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6376">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6379">
					<section type="none" id="sidelem4x6380">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6385">
								<item>
									<label>•</label>
									<para>Nutritional status: yellow and dark green vegetables, yellow/orange fruits, vit-A–fortified foods, liver, egg yolks</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6393">
							<label>•</label>
							<sec_title>Vit A deficiency</sec_title>
							<para>
								<list id="lidelem4x6393">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Vit A deficiency:</emphasis> decreased growth; night blindness; dry, brittle nails; hair loss; urinary stones; increased infection; hyperkeratosis of skin; drying of cornea</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6397">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6401">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased growth rate, weight; absence of dry skin and mucous membranes, night blindness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6407">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6411">
								<item>
									<label>•</label>
									<para>That, if dose is missed, it should be omitted</para>
								</item>
								<item>
									<label>•</label>
									<para>That ophthalmic exams may be required periodically throughout therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use mineral oil while taking this product</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of nausea, vomiting, lip cracking, loss of hair, headache</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to take more than prescribed amount</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="23" status="active">
			<mono_name>vitamin C (ascorbic acid) (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(a-skor′bic)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x64506">Acerola C</tradename>
					<tradename id="tnidelem4x64505">
						<country code="CAN">Apo-C </country>
					</tradename>
					<tradename id="tnidelem4x64504">Ascor L-500</tradename>
					<tradename id="tnidelem4x64503">Cenolate</tradename>
					<tradename id="tnidelem4x64502">Equaline Vitamin C</tradename>
					<tradename id="tnidelem4x64501">Walgreens Gold Seal</tradename>
					<tradename id="tnidelem4x64500">and many more</tradename>
				</tradenames>
				<class type="func"> Vit C—water-soluble vitamin</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x6459">
				<sec_title>Action:</sec_title>
				<para>Wound healing, collagen synthesis, antioxidant, carbohydrate metabolism</para>
			</section>
			<section type="uses" id="sidelem4x6464">
				<sec_title>Uses:</sec_title>
				<para>Vit C deficiency, scurvy; delayed wound, bone healing; chronic disease; urine acidification; before gastrectomy; dietary supplement</para>
				<section type="none" id="sidelem4x6469">
					<section type="none" id="sidelem4x6470">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Common cold prevention</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6475">
				<sec_title>Contraindications:</sec_title>
				<para>Tartrazine, sulfite sensitivity; G6PD deficiency</para>
				<section type="none" id="sidelem4x6480">
					<section type="none" id="sidelem4x6481">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), gout, diabetes, renal calculi (large doses)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6486">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6489">
					<section type="none" id="sidelem4x6490">
						<sec_title>Dietary supplementation</sec_title>
						<section type="none" id="sidelem4x6498">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x6498">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> 50-500 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6505">
							<label>•</label>
							<sec_title>Child 14-18 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6505">
									<item>
										<label>•</label>
										<para> 65 mg (female), 75 mg (male)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6512">
							<label>•</label>
							<sec_title>Child 9-13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6512">
									<item>
										<label>•</label>
										<para> 45 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6519">
							<label>•</label>
							<sec_title>Child 4-8 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6519">
									<item>
										<label>•</label>
										<para> 25 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6526">
							<label>•</label>
							<sec_title>Child 1-3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6526">
									<item>
										<label>•</label>
										<para> 15 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6533">
							<label>•</label>
							<sec_title>Infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6533">
									<item>
										<label>•</label>
										<para> 40-50 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6537">
						<sec_title>Scurvy</sec_title>
						<section type="none" id="sidelem4x6545">
							<label>•</label>
							<sec_title>Adult<route> PO/SUBCUT/IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6545">
									<item>
										<label>•</label>
										<para> 100-250 mg/day × 2 wk, then 50 mg or more daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6552">
							<label>•</label>
							<sec_title>Child<route> PO/SUBCUT/IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6552">
									<item>
										<label>•</label>
										<para> 100-300 mg/day × 2 wk, then 35 mg or more daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6556">
						<sec_title>Wound healing/chronic disease/fracture (may be given with zinc)</sec_title>
						<section type="none" id="sidelem4x6564">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IM/IV/PO</route></sec_title>
							<para>
								<list id="lidelem4x6564">
									<item>
										<label>•</label>
										<para> 200-500 mg/day for 1-2 mo</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6571">
							<label>•</label>
							<sec_title>Child<route> SUBCUT/IM/IV/PO</route></sec_title>
							<para>
								<list id="lidelem4x6571">
									<item>
										<label>•</label>
										<para> 100-200 mg added doses for 1-2 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6575">
						<sec_title>Urine acidification</sec_title>
						<section type="none" id="sidelem4x6583">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x6583">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> 4-12 g/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6590">
							<label>•</label>
							<sec_title>Child</sec_title>
							<para>
								<list id="lidelem4x6590">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child:</emphasis> 500 mg q6-8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6594">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 50, 100, 250, 500, 1000, 1500 mg; effervescent tabs 1000 mg; chewable tabs 100, 250, 500 mg; timed-release tabs 500, 750, 1000, 1500 mg; timed-release caps 500 mg; crys 4 g/tsp; powder 4 g/tsp; liq 35 mg/0.6 ml; sol 100 mg/ml; syr 20 mg/ml, 500 mg/5 ml; inj SUBCUT, IM, IV 100, 250, 500 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x6599">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6602">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x6606">
									<item>
										<label>•</label>
										<para>Do not crush or chew ext rel tabs or caps</para>
									</item>
									<item>
										<label>•</label>
										<para>Caps may be opened and contents mixed with jelly</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6617">
							<sec_title>IV, direct route</sec_title>
							<para>
								<list id="lidelem4x6621">
									<item>
										<label>•</label>
										<para>100 mg undiluted by direct IV over at least 1 min; rapid infusion may cause fainting</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6627">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x6631">
									<item>
										<label>•</label>
										<para>Diluted with D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">5</emphasis>NaCl, NS, LR, Ringer’s, sodium lactate and given over 15 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6643">
						<sec_title>Syringe compatibilities:</sec_title>
						<para> Metoclopramide, aminophylline, theophylline</para>
					</section>
					<section type="none" id="sidelem4x6648">
						<sec_title>Y-site compatibilities:</sec_title>
						<para> Warfarin</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6653">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6656">
					<section type="none" id="sidelem4x6657">
						<sec_title>CNS:</sec_title>
						<para> Headache, insomnia, dizziness, fatigue, flushing</para>
					</section>
					<section type="none" id="sidelem4x6662">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, anorexia, heartburn, cramps</para>
					</section>
					<section type="none" id="sidelem4x6667">
						<sec_title>GU:</sec_title>
						<para> Polyuria, urine acidification, oxalate/urate renal stones, dysuria</para>
					</section>
					<section type="none" id="sidelem4x6672">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemolytic anemia in patients with G6PD</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6679">
						<sec_title>INTEG:</sec_title>
						<para> Inflammation at inj site</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6684">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x6687">
					<section type="none" id="sidelem4x6688">
						<sec_title>PO/INJ:</sec_title>
						<para> Readily absorbed PO, metabolized in liver; unused amounts excreted in urine (unchanged), metabolites; crosses placenta, breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6693">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x6696">
					<section type="none" id="sidelem4x6697">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False negative:</emphasis> occult blood, urine bilirubin, leukocyte determination</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6704">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6707">
					<section type="none" id="sidelem4x6708">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6712">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; urine pH (acidification)</para>
								</item>
								<item>
									<label>•</label>
									<para>Ascorbic acid levels throughout treatment if continued deficiency is suspected</para>
								</item>
								<item>
									<label>•</label>
									<para>Nutritional status: citrus fruits, vegetables</para>
								</item>
								<item>
									<label>•</label>
									<para>Inj sites for inflammation</para>
								</item>
								<item>
									<label>•</label>
									<para>Thrombophlebitis if receiving large dose</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6738">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6742">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of anorexia, irritability, pallor, joint pain, hyperkeratosis, petechiae, poor wound healing</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6748">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6752">
								<item>
									<label>•</label>
									<para>Necessary foods to include in diet, such as citrus fruits</para>
								</item>
								<item>
									<label>•</label>
									<para>That smoking decreases vit C levels; not to exceed prescribed dose; that excesses will be excreted in urine, except when taking timed-release forms</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="24" status="active">
			<mono_name>vitamin E (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x67690">Aquasol E</tradename>
				</tradenames>
				<class type="func"> Vit E</class>
				<class type="chem"> Fat soluble</class>
				<class type="preg">Pregnancy category <preg cat="A">A</preg></class>
			</info>
			<section type="actions" id="sidelem4x6779">
				<sec_title>Action:</sec_title>
				<para>Needed for digestion and metabolism of polyunsaturated fats; decreases platelet aggregation, blood clot formation; promotes normal growth and development of muscle tissue, prostaglandin synthesis</para>
			</section>
			<section type="uses" id="sidelem4x6784">
				<sec_title>Uses:</sec_title>
				<para>Vit E deficiency, impaired fat absorption, hemolytic anemia in premature neonates, prevention of retrolental fibroplasia, sickle cell anemia, supplement for malabsorption syndrome</para>
			</section>
			<section type="contra" id="sidelem4x6789">
				<sec_title>Contraindications:</sec_title>
				<para>IV use in infants</para>
				<section type="none" id="sidelem4x6794">
					<section type="none" id="sidelem4x6795">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="A">A</preg>), anemia, breastfeeding, hypoprothrombinemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6800">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6803">
					<section type="none" id="sidelem4x6804">
						<sec_title>Deficiency</sec_title>
						<section type="none" id="sidelem4x6812">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6812">
									<item>
										<label>•</label>
										<para> 60-75 international units/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6819">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6819">
									<item>
										<label>•</label>
										<para> 1 international units/kg (malabsorption)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6823">
						<sec_title>Prevention of deficiency</sec_title>
						<section type="none" id="sidelem4x6831">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6831">
									<item>
										<label>•</label>
										<para> 30 international units/day;  apply to affected areas</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6841">
							<label>•</label>
							<sec_title>Infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6841">
									<item>
										<label>•</label>
										<para> 5 international units/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6845">
						<sec_title>Available forms:</sec_title>
						<para> Caps 100, 200, 400, 500, 600, 1000 international units; tabs 100, 200, 400 international units; drops 15 mg/0.3 ml; chew tabs 400 units; ointment; cream; lotion; oil</para>
					</section>
					<section type="none" id="sidelem4x6850">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6853">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x6857">
									<item>
										<label>•</label>
										<para>Administer with or after meals</para>
									</item>
									<item>
										<label>•</label>
										<para>Chew chewable tabs well</para>
									</item>
									<item>
										<label>•</label>
										<para>Sol may be dropped in mouth or mixed with food</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight, light-resistant container</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6878">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x6882">
									<item>
										<label>•</label>
										<para>To moisturize dry skin</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6888">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6891">
					<section type="none" id="sidelem4x6892">
						<sec_title>CNS:</sec_title>
						<para> Headache, fatigue</para>
					</section>
					<section type="none" id="sidelem4x6897">
						<sec_title>CV:</sec_title>
						<para> Increased risk for thrombophlebitis</para>
					</section>
					<section type="none" id="sidelem4x6902">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision</para>
					</section>
					<section type="none" id="sidelem4x6907">
						<sec_title>GI:</sec_title>
						<para> Nausea, cramps, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x6912">
						<sec_title>GU:</sec_title>
						<para> Gonadal dysfunction</para>
					</section>
					<section type="none" id="sidelem4x6917">
						<sec_title>INTEG:</sec_title>
						<para> Sterile abscess, contact dermatitis</para>
					</section>
					<section type="none" id="sidelem4x6922">
						<sec_title>META:</sec_title>
						<para> Altered metabolism of hormones (thyroid, pituitary, adrenal), altered immunity</para>
					</section>
					<section type="none" id="sidelem4x6927">
						<sec_title>MS:</sec_title>
						<para> Weakness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6932">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x6935">
					<section type="none" id="sidelem4x6936">
						<sec_title>PO:</sec_title>
						<para> Metabolized in liver, excreted in bile</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6941">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of oral anticoagulants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—cholestyramine, colestipol, mineral oil, sucralfate</para>
			</section>
			<section type="considerations" id="sidelem4x6952">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6955">
					<section type="none" id="sidelem4x6956">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6960">
								<item>
									<label>•</label>
									<para>Nutritional status: wheat germ; dark green, leafy vegetables; nuts; eggs; liver; vegetable oils; dairy products; cereals</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6966">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6970">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of hemolytic anemia, adequate vit E levels, improvement in skin lesions, decreased edema</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6976">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6980">
								<item>
									<label>•</label>
									<para>About the necessary foods for diet</para>
								</item>
								<item>
									<label>•</label>
									<para>To omit dose if missed</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid vitamin supplements unless directed by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="25" status="active" ha="yes">
			<mono_name> vorapaxar</mono_name>
			<info>
				<pronunciation>(vor′a-pax′ar)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x70030">Zontivity</tradename>
				</tradenames>
				<class type="func"> Platelet inhibitor</class>
			</info>
			<section type="actions" id="sidelem4x7009">
				<sec_title>Action:</sec_title>
				<para> Antagonizes the protease-activated receptor-1 (PAR-1) expressed on platelets</para>
			</section>
			<section type="uses" id="sidelem4x7014">
				<sec_title>Uses:</sec_title>
				<para> Secondary myocardial infarction prophylaxis or stroke prophylaxis or thrombosis prophylaxis for reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease</para>
			</section>
			<section type="contra" id="sidelem4x7019">
				<sec_title>Contraindications:</sec_title>
				<para>
					<bbw> Bleeding, intracranial bleeding, stroke</bbw>
				</para>
				<section type="none" id="sidelem4x7032">
					<section type="none" id="sidelem4x7033">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, coronary artery bypass graft surgery (CABG), geriatric patients, hepatic disease, labor, obstetric delivery, pregnancy (B), renal impairment, surgery</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7038">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7046">
					<label>•</label>
					<sec_title>Adults<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7046">
							<item>
								<label>•</label>
								<para> 2.08 mg once daily with aspirin and/or clopidogrel</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7050">
					<section type="none" id="sidelem4x7051">
						<sec_title>Available forms:</sec_title>
						<para> Tab 2.08 mg</para>
					</section>
					<section type="none" id="sidelem4x7056">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7060">
								<item>
									<label>•</label>
									<para>May be administered without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7066">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7069">
					<section type="none" id="sidelem4x7070">
						<sec_title>CNS:</sec_title>
						<para> Depression</para>
					</section>
					<section type="none" id="sidelem4x7075">
						<sec_title>EENT:</sec_title>
						<para> Diplopia, retinopathy</para>
					</section>
					<section type="none" id="sidelem4x7080">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, bleeding</para>
					</section>
					<section type="none" id="sidelem4x7085">
						<sec_title>MISC:</sec_title>
						<para> Rash</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7090">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Within 1 week of treatment reaches ≥80% inhibition of thrombin receptor, half-life 3-4 days, terminal half-life is approximately 8 days, protein binding 99%, primarily eliminated feces; peak 1 hr</para>
			</section>
			<section type="interactions" id="sidelem4x7095">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x7098">
					<section type="none" id="sidelem4x7099">
						<sec_title>Increase:</sec_title>
						<para> bleeding risk—anticoagulants, aspirin, NSAIDs, other platelet inhibitors, SSRIs, rifampin, SNRIs, thrombolytics, CYP3A inhibitors, ethyl estradiol, calcium channel blockers</para>
					</section>
					<section type="none" id="sidelem4x7104">
						<sec_title>Decrease:</sec_title>
						<para> vorapaxar effect—CYP3A inducers</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7109">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7112">
					<section type="none" id="sidelem4x7113">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>For bleeding, including intracranial bleeding and stroke during treatment</bbw>
						</para>
						<para>
							<list id="lidelem4x7126">
								<item>
									<label>•</label>
									<para>Bleeding should be suspected in any patient presenting with hypotension who has recently undergone surgery, coronary angiography, percutaneous coronary intervention (PCI), or CABG</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7132">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7136">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of MI, stroke</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7142">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7146">
								<item>
									<label>•</label>
									<para>To report any unusual bruising, bleeding to prescriber; that it may take longer to stop bleeding</para>
								</item>
								<item>
									<label>•</label>
									<para>To take without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="26" status="active">
			<mono_name>voriconazole (Rx)</mono_name>
			<info>
				<pronunciation>(vohr-i-kahn′a-zol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x71620">Vfend</tradename>
				</tradenames>
				<class type="func"> Antifungal, systemic</class>
				<class type="chem"> Triazole derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7172">
				<para>
					<confusion>
						<tradename id="tnidelem4x71720">Vfend</tradename>
						<drug type="generic" refid="idelem4x71720">Venofer</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7176">
				<sec_title>Action:</sec_title>
				<para>Inhibits fungal CYP450-mediation demethylation; needed for biosynthesis; causes leakage from cell membrane</para>
			</section>
			<section type="uses" id="sidelem4x7181">
				<sec_title>Uses:</sec_title>
				<para>Invasive aspergillosis, serious fungal infections (<emphasis style="italic">Candida</emphasis> sp., <emphasis style="italic">Scedosporium apiospermum, Fusarium</emphasis> sp., <emphasis style="italic">Monosporium, Apiospermum</emphasis>)</para>
				<section type="none" id="sidelem4x7195">
					<section type="none" id="sidelem4x7196">
						<sec_title>Unlabeled uses:</sec_title>
						<para> <emphasis style="italic">Acremonium</emphasis> sp., <emphasis style="italic">Blastomyces dermatitidis, Coccidioides immitis, Cryptococcus neoformans,</emphasis> febrile neutropenia, fungal keratitis, <emphasis style="italic">Histoplasma capsulatum,</emphasis> oropharyngeal candidiasis, <emphasis style="italic">Rhodotorula</emphasis> sp., <emphasis style="italic">Scedosporium</emphasis> sp., cutaneous aspergillosis, candidemia (premature neonates), fungal infections in children ≥12 yr</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x7216">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, children, hypersensitivity, severe bone marrow depression, severe hepatic disease</para>
				<section type="none" id="sidelem4x7221">
					<section type="none" id="sidelem4x7222">
						<sec_title>Precautions:</sec_title>
						<para> Renal disease (IV); patients of Asian/African descent; cardiomyopathy, cholestasis, chemotherapy, lactase deficiency, visual disturbances, renal failure, pancreatitis, QT prolongation, hypokalemia; ventricular dysrhythmias, torsades de pointes</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7227">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7230">
					<section type="none" id="sidelem4x7231">
						<sec_title>Esophageal candidiasis</sec_title>
						<section type="none" id="sidelem4x7239">
							<label>•</label>
							<sec_title>Adult/geriatric/child ≥12 yr and ≥40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7239">
									<item>
										<label>•</label>
										<para> 200 mg q12hr; , 100 mg q12hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7249">
							<label>•</label>
							<sec_title>Adult/geriatric/child ≥12 yr<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x7249">
									<item>
										<label>•</label>
										<para> Loading dose 6 mg/kg q12hr × 2 dose, then 3-4 mg/kg q12hr; may switch to oral dosing</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7253">
						<sec_title>Candidemia of the skin, kidney, bladder wall, abdomen (nonneutropenic patients)</sec_title>
						<section type="none" id="sidelem4x7261">
							<label>•</label>
							<sec_title>Adult/child ≥12 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x7261">
									<item>
										<label>•</label>
										<para> loading dose 6 mg/kg q12hr × 24 hr, then 3-4 mg/kg q12hr × ≥14 days and ≥7 days after resolution of symptoms;  after loading dose  200 mg q12hr × ≥14 days and ≥7 days after resolution of symptoms;  100 mg q12hr × ≥14 days and ≥7 days after resolution of symptoms</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7274">
						<sec_title>Invasive aspergillosis</sec_title>
						<section type="none" id="sidelem4x7282">
							<label>•</label>
							<sec_title>Adults/adolescents<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x7282">
									<item>
										<label>•</label>
										<para> 6 mg/kg q12hr (loading dose), then 4 mg/kg q12hr, may reduce to 3 mg/kg q12hr if intolerable</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7289">
							<label>•</label>
							<sec_title>Child ≥12 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x7289">
									<item>
										<label>•</label>
										<para> 6 mg/kg q12hr, then 4 mg/kg q12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7293">
						<sec_title>CNS blastomycosis/blastomycosis meningitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x7301">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7301">
									<item>
										<label>•</label>
										<para> 200-400 mg bid × at least 12 mo and until resolution of CSF abnormalities</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7305">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x7313">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;50 ml/min, use orally only</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7316">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x7324">
							<label>•</label>
							<sec_title>Adult<route> PO 6 mg/kg q12hr × 2 doses, then 2 mg/kg q12hr or 100 mg q12hr if &gt;40 kg; 50 mg q12hr if &lt;40 kg</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7327">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50, 200 mg; powder for inj, lyophilized 200 mg, powder for oral susp 45 g (40 mg/ml after reconstitution)</para>
					</section>
					<section type="none" id="sidelem4x7332">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7335">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x7339">
									<item>
										<label>•</label>
										<para>Oral susp: tap bottle; add 46 ml of water to bottle; shake well; remove cap; push bottle adaptor into neck of bottle; replace cap; write expiration date (14 days); shake well before each use; administer using only oral dispenser supplied, 1 hr before or after meals; tabs and susp may be interchanged</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature (powder, tabs)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7350">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x7354">
									<item>
										<label>•</label>
										<para>Product only after C&amp;S confirms organism, product needed to treat condition; make sure product used in life-threatening infections</para>
									</item>
									<item>
										<label>•</label>
										<para>Reconstitute powder with 19 ml water for inj to 10 mg/ml; shake until dissolved; infuse over 1-2 hr at concentration of ≤5 mg/ml; do not admix with other products, 4.2% sodium bicarbonate infusion</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B liposome, ampicillin, ampicillin/sulbactam, anidulafungin, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium acetate/chloride/gluconate, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cytarabine, dacarbazine, DACTINomycin, DAPTOmycin, DAUNOrubicin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doripenem, doxacurium, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, ifosfamide, imipenem/cilastatin, inamrinone, insulin, irinotecan, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, metaraminol, methohexital, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, mitoMYcin, morphine, nafcillin, nalbuphine, naloxone, niCARdipine, nitroglycerin, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, pamidronate, pancuronium, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, piperacillin/tazobactam, potassium chloride/phosphates, procainamide, promethazine, propranolol, quinupristin/dalfopristin, remifentanil, rocuronium, sodium acetate/bicarbonate/phosphates, streptozocin, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin/clavulanate, tirofiban, tobramycin, topotecan, trimethobenzamide, trimethoprim/sulfamethoxazole, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7369">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7372">
					<section type="none" id="sidelem4x7373">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> paresthesias, peripheral neuropathy, <emphasis style="italic">hallucinations,</emphasis> psychosis, EPS, depression, Guillain-Barré syndrome, insomnia, suicidal ideation, dizziness, fever</para>
					</section>
					<section type="none" id="sidelem4x7384">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Tachycardia,</emphasis> hypo/hypertension, vasodilation, <emphasis style="bold">atrial arrhythmias, atrial fibrillation, AV block, bradycardia, CHF, MI, QT prolongation, torsades de pointes,</emphasis> peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x7395">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, eye hemorrhage, <emphasis style="bold">visual disturbances</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7402">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea,</emphasis> cramps, <emphasis style="bold">hemorrhagic gastroenteritis, acute hepatic failure, hepatitis, intestinal perforation, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7412">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Hypokalemia,</emphasis> azotemia, <emphasis style="bold">renal tubular necrosis, permanent renal impairment, anuria, oliguria</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7422">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, <emphasis style="bold">eosinophilia,</emphasis> hypomagnesemia, <emphasis style="bold">thrombocytopenia, leukopenia, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7432">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Burning, irritation,</emphasis> pain, necrosis at inj site with extravasation, dermatitis, <emphasis style="italic">rash,</emphasis> photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x7443">
						<sec_title>MISC:</sec_title>
						<para> Respiratory disorder</para>
					</section>
					<section type="none" id="sidelem4x7448">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome, toxic epidermal necrolysis, sepsis; melanoma,</emphasis> photosensitivity reactions</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7456">
				<sec_title>Pharmacokinetics</sec_title>
				<para>By CYP3A4, CYP2C9 enzymes; max serum concentration 1-2 hr after dosing; eliminated via hepatic metabolism; protein binding 58%; elimination half-life 6 hr (dose dependent)</para>
			</section>
			<section type="interactions" id="sidelem4x7461">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of benzodiazepines, calcium channel blockers, cycloSPORINE, ergots, HMG-CoA reductase inhibitors, pimozide, quiNIDine, prednisoLONE, sirolimus, sulfonylureas, tacrolimus, vinca alkaloids, warfarin, rifabutin, proton pump inhibitors, NNRTIs, protease inhibitors, phenytoin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> nephrotoxicity—other nephrotoxic antibiotics (aminoglycosides, CISplatin, vancomycin, cycloSPORINE, polymyxin B)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypokalemia—corticosteroids, digoxin, skeletal muscle relaxants, thiazides</para>
				<para>
					<emphasis alert="nurse">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin), arsenic trioxide, levomethadyl; CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, ziprasidone)</emphasis>
				</para>
				<section type="none" id="sidelem4x7481">
					<section type="none" id="sidelem4x7482">
						<sec_title>Drug/Herb</sec_title>
						<section type="none" id="sidelem4x7490">
							<label>•</label>
							<sec_title>
								<route>Do not use with St. John’s wort</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7493">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x7497">
								<item>
									<label>•</label>
									<para>Avoid use with high-fat meals, take 1 hr before or after meal</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7503">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST/ALT, alk phos, creatinine, bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb/Hct, platelets, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7514">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7517">
					<section type="none" id="sidelem4x7518">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7523">
								<item>
									<label>•</label>
									<para>VS q15-30min during first infusion; note changes in pulse, B/P</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7528">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; watch for decreasing urinary output, change in specific gravity; discontinue product to prevent permanent damage to renal tubules</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7533">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, potassium, sodium, calcium, magnesium, q2wk; BUN, creatinine weekly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7538">
								<item>
									<label>•</label>
									<para>Weight weekly; if weight increases &gt;2 lb/wk, edema is present; renal damage should be considered</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7544">
								<item>
									<para>
										<emphasis alert="nurse">Renal toxicity: increasing BUN, serum creatinine; if BUN is &gt;40 mg/dl or if serum creatinine &gt;3 mg/dl, product may be discontinued or dosage reduced</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7550">
								<item>
									<para>
										<emphasis alert="nurse">Hepatotoxicity: increasing AST, ALT, alk phos, bilirubin, baseline and periodically</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7558">
							<label>•</label>
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x7558">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reaction:</emphasis> dermatitis, rash; product should be discontinued, antihistamines (mild reaction) or epinephrine (severe reaction) administered</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7565">
							<label>•</label>
							<sec_title>Hypokalemia</sec_title>
							<para>
								<list id="lidelem4x7565">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypokalemia:</emphasis> anorexia, drowsiness, weakness, decreased reflexes, dizziness, increased urinary output, increased thirst, paresthesias</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7572">
							<label>•</label>
							<sec_title>Ototoxicity</sec_title>
							<para>
								<list id="lidelem4x7572">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ototoxicity:</emphasis> tinnitus (ringing, roaring in ears), vertigo, loss of hearing (rare); visual disturbance</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7579">
							<label>•</label>
							<sec_title>QT prolongation<route> ECG, ejection fraction; assess for chest pain, palpitations, dyspnea</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7582">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7586">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased fever, malaise, rash, negative C&amp;S for infecting organism</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7592">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7597">
								<item>
									<label>•</label>
									<para>That long-term therapy may be needed to clear infection (2 wk-3 mo, depending on type of infection)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7602">
								<item>
									<label>•</label>
									<para>To notify prescriber of bleeding, bruising, soft-tissue swelling, dark urine, persistent nausea or diarrhea, headache, rash, yellow skin/eyes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7607">
								<item>
									<label>•</label>
									<para>Take 1 hr before or after meal (PO)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7612">
								<item>
									<label>•</label>
									<para>Do not drive at night because of vision changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7617">
								<item>
									<label>•</label>
									<para>Avoid strong, direct sunlight</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7625">
							<label>•</label>
							<sec_title>
								<route>Women of childbearing age should use effective contraceptive, pregnancy (D)</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="27" status="active">
			<mono_name>vortioxetine</mono_name>
			<info>
				<pronunciation>(vor′tye-ox′e-teen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x76330">Brintellix</tradename>
				</tradenames>
				<class type="func"> Antidepressant</class>
				<class type="chem"> Serotonin modulator</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x7643">
				<sec_title>Action:</sec_title>
				<para>Reuptake inhibition at the serotonin transporter and agonist, or antagonist effects at serotonin receptors</para>
			</section>
			<section type="uses" id="sidelem4x7648">
				<sec_title>Uses:</sec_title>
				<para>Major depressive disorder in adults</para>
			</section>
			<section type="contra" id="sidelem4x7653">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, MAOI therapy</para>
				<section type="none" id="sidelem4x7658">
					<section type="none" id="sidelem4x7659">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, seizure disorder, hypersensitivity, bipolar disorder, hyponatremia, hypovolemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7664">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7672">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7672">
							<item>
								<label>•</label>
								<para> 10 mg/day, may start with 5 mg/day initially, increase to 20 mg/day as tolerated, max 20 mg/day; poor metabolizers of CYP2D6 max 10 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7676">
					<section type="none" id="sidelem4x7677">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 20 mg</para>
					</section>
					<section type="none" id="sidelem4x7682">
						<sec_title>Administer:</sec_title>
						<para> Without regard to food</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7687">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7690">
					<section type="none" id="sidelem4x7691">
						<sec_title>CNS:</sec_title>
						<para> Flushing, mania, serotonin syndrome, vertigo, dizziness, suicidal attempts</para>
					</section>
					<section type="none" id="sidelem4x7696">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea, dyspnea, constipation, vomiting, flatulence</para>
					</section>
					<section type="none" id="sidelem4x7701">
						<sec_title>GU:</sec_title>
						<para> Impotence</para>
					</section>
					<section type="none" id="sidelem4x7706">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus</para>
					</section>
					<section type="none" id="sidelem4x7711">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Serotonin syndrome, neonatal abstinence syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7718">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 98%, excreted in urine (59%), feces (26%)</para>
			</section>
			<section type="interactions" id="sidelem4x7723">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of tricyclics; use cautiously</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome—serotonin receptor agonists, SSRIs, traMADol, lithium, MAOIs, traZODone, SNRIs (venlafaxine, DULoxetine)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, salicylates, thrombolytics, anticoagulants, antiplatelets</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS effects—barbiturates, sedative/hypnotics, other CNS depressants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> vortioxetine levels—carBAMazepine</para>
				<section type="none" id="sidelem4x7745">
					<section type="none" id="sidelem4x7746">
						<sec_title>Drug/Herb:</sec_title>
						<para>
							<emphasis alert="lifethreat">Increase: serotonin syndrome—St. John’s wort</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7752">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7755">
					<section type="none" id="sidelem4x7756">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Mental status: mood, sensorium, affect, suicidal tendencies, increase in psychiatric symptoms, depression, panic</bbw>
						</para>
						<section type="none" id="sidelem4x7773">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> increased heart rate, sweating, dilated pupils, tremors, twitching, hyperthermia, agitation</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7776">
								<item>
									<label>•</label>
									<para>Alcohol consumption; if alcohol is consumed, hold dose until <emphasis style="smallcaps">am</emphasis></para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7786">
							<label>•</label>
							<sec_title>Sexual dysfunction</sec_title>
							<para>
								<list id="lidelem4x7786">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Sexual dysfunction:</emphasis> impotence</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7790">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7794">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression</para>
								</item>
								<item>
									<label>•</label>
									<para>Children, suicidal ideation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7805">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7810">
								<item>
									<label>•</label>
									<para>That therapeutic effect may take several wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7815">
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities that require alertness because of drowsiness, dizziness, blurred vision; to report signs, symptoms or bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7820">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants
<bbw>That suicidal ideas, behaviors may occur in children or young adults</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7837">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnant, planning to become pregnant, or breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>